

A

- AA (Alcoholics Anonymous), 297–298
- AACP (American Association of Child and Adolescent Psychiatry), 388
- AAIDD (American Association on Intellectual and Developmental Disabilities), 391
- ABAB design, 96
- Abilify (aripiprazole), 259, 402
- Abkhazia, 407
- Abuse, recovered memories of, 216
- Academic achievement, 369
- Acamprosate, 299
- ACC (anterior cingulate cortex), 228
- Acceptance
 - and commitment therapy (ACT), 42, 234
 - in dialectical behavior therapy, 454
- Acculturation, 327
- Acetaminophen, 281
- Acocella, Joan, 219
- Acrophobia, 154
- ACT (acceptance and commitment therapy), 42, 234
- Actigraphy, 126–127
- Acute stress disorder (ASD), 57, 199, 207, 366, 383–384, 395
- Adaptive behavior, 391, 401
- Adderall, 38, 283, 372
- Addict, term, 269
- Addiction, 268–269. *See also* Caffeine
- Additions. *See* Copy number variations (CNVs)
- ADH (alcohol dehydrogenases), 289
- ADHD. *See* Attention-deficit/hyperactivity disorder (ADHD)
- Adler, Alfred, 18
- Adolescents
 - ADHD in, 369
 - anxiety in, 385–387
 - body dissatisfaction for, 327
 - bulimia nervosa in, 314
 - and cyclothymic disorder, 120–121
 - depression in, 380–389. *See also* Treatment of Adolescents with Depression Study (TADS)
 - eating disorder prevention for, 332
 - and lifetime prevalence rates of mood and anxiety disorders, 380
 - limited antisocial behavior, 374–375
 - personality disorders in, 433, 441
 - and Prozac, 383
 - and schizophrenia, 244
 - smoking and negative life events for, 293
 - substance use disorder in, 289, 294
 - substance use prevention for, 305
- Adolescent-onset conduct disorder, 375
- Adoptees method, 93
- Adoption studies, 247, 370, 376, 440
- Adrenal cortex, 37
- Adrenocorticotrophic hormone, 37
- Adult antisocial personality disorder, 64
- Adulthood
 - ADHD in, 369–370
 - autism spectrum disorder in, 398
 - conduct disorder in, 375
- Adversity, childhood. *See* Childhood adversity
- Advertising, 295, 316–317
- Advocacy groups, 5
- Affect. *See also* Emotion(s)
 - blunted, 241
 - ideal, 45
 - negative, 293–294, 435
- Affection, parental, 437
- African Americans
 - alcohol use disorders for, 271
 - antipsychotic use by, 263
 - cultural bias in assessment with, 80–81
 - culturally competent treatment of, 103
 - eating disorders for, 327
 - PTSD for, 202
 - schizophrenia for, 238
 - and stereotype threat, 74
 - tobacco use by, 273, 274
 - vascular dementia for, 420–421
- Age and aging, 255–256, 325, 406–410. *See also* Late life
- Age effects, 408
- Age regression, 221
- Aggression, 40
 - and ADHD, 366
 - and alcohol use, 293–294
 - and bipolar disorders, 471–472
 - and conduct disorder, 372–373, 375–376
- Agitation, 422
- Agoraphobia, 65, 153
- clinical description of, 158
- in late life, 411
- prevalence of, 154
- treatments for, 99, 178
- AIDS epidemic, 336
- Air Force, 148
- Alabama, 475
- alAl-Bh-Razi, 9
- Alarm reaction, 71
- Alaska, 276
- Alaska Natives, 271, 274
- Alba, Jessica, 324
- Al-Balkhi, 9
- Alcohol
 - and ADHD medications, 383
 - and anxiety/stress, 293
 - in cross-national use studies, 294
 - expectancies and expectations about, 293–294
 - long-term effects of, 272–273
 - and neurobiology of craving, 290
 - and nicotine use, 270
 - and paraphilic disorders, 357–360
 - reported use of, 268
 - short-term effects of, 271–272
 - social networks and use of, 295
 - U.S. population reporting use of, 267–270
- Alcohol abuse, 91, 99, 155, 411
- Alcohol dehydrogenases (ADH), 289
- Alcohol dependence, 46, 110, 291
- Alcoholics anonymous (AA), 297–298
- Alcoholic, term, 269
- Alcohol myopia, 293
- Alcohol use disorder, 64, 270–273
 - gender differences in, 45
 - genetic influences, 288–289
 - long-term effect, 272–273
 - and marital distress, 67
 - and missed workdays, 67
 - prevalence of, 270–271
 - and risky decision making, 292
 - short-term effects of, 271–272
 - treatment of, 297–300
- ALI (American Law Institute) guidelines, 459–460
- Alleles, 29
- Alogia, 241
- Alpha level. *See* Statistical significance
- Alternate-form reliability, 54. *See also* Reliability
- Alternative DSM-5 Model for Personality Disorders, 431, 434–436
- Alternative hypotheses, 86
- Alzheimer, Alois, 415
- Alzheimer's Association, 414
- Alzheimer's disease, 415–419
 - and caregiver support, 422–423
 - global burden of, 406
 - and informed consent, 481–482
 - medications for treating, 422
- Amendment I, 457
- Amendment IV, 457
- Amendment V, 457
- Amendment VI, 457
- Amendment VIII, 457
- Amendment XIII, 457
- Amendment XIV, 457
- Amendment XV, 457
- American Association of Child and Adolescent Psychiatry (AACP), 388
- American Association
 - on Intellectual and Developmental Disabilities (AAIDD), 391
- American Indians. *See* Native Americans
- American Law Institute (ALI) guidelines, 459–460
- American Lung Association, 275
- American Psychiatric Association (APA), 57, 59, 140, 147, 258, 480
- American Psychological Association Board of Trustees, 434
- America's Law Enforcement and Mental Health Project Act, 478
- Amnesia, dissociative. *See* Dissociative amnesia
- Amphetamines, 45, 283–285
- Amygdala, 34
 - and autism spectrum disorder, 401
 - and borderline personality disorder, 400
 - and conduct disorder, 376
 - emotion and reward processing, involvement in, 123–125
 - and marijuana, 279
 - neurobiological correlates, 164–165
 - and psychopathy, 443–444
 - and PTSD, 201–202
 - and rewards, valuing of, 290, 292
- Anafranil (clomipramine), 194
- Analogue experiments, 105–107
- Analytical psychology, 18
- Anatomical connectivity, 35
- Androgens, 358, 361
- Anesthesia, 225
- Angel dust. *See* PCP (phencyclidine)
- Anhedonia, 114
- Animal hoarding, 187
- Animal studies, 166, 283
- "Anna O.," 225
- Anorexia nervosa, 309
 - clinical description of, 309–312
 - cognitive behavioral/emotional influences of, 321–322
 - cross-cultural studies of, 32–327
 - DSM-5 criteria for, 309, 311
 - genetic influences in, 319

- Anorexia nervosa (*continued*)
 nervosa prognosis, 312
 neurobiological influences in, 320–321
 other eating disorders vs., 313–318
 personality influences on, 327–328
 physical consequences of, 312
 psychological treatment of, 346
- ANS. *See* Autonomic nervous system (ANS)
- Antabuse, 299, 300
- Antagonism, 435
- Anterior cingulate, 34, 123–124
- Anterior cingulate cortex (ACC), 124, 165, 189, 218, 228, 272, 292, 445, 448
- Anterior insula, 228
- Anticipatory pleasure, 240
- Anticonvulsants, 138, 141
- Antidepressants, 38, 138–139
 for anxiety disorders, 177, 179
 for childhood disorders, 382–383
 controversies, 383
 for dementia, 422
 for eating disorders, 320–321, 329, 331
 for major depressive disorder, 138–141
 for obsessive-compulsive and related disorders, 194
 for paraphilic disorders, 361
 for personality disorders, 452–453
 and sexual dysfunction, 346, 351
 for somatic symptom/illness anxiety disorder, 234
 and suicidality, 145
 U.S. use of, 134
 warnings on, 100
- Antihistamines, 258
- Anti-NMDA-receptor autoimmune encephalitis, 63
- Antipsychotic drugs (antipsychotics), 38, 100
 for bipolar disorder, 141
 and brain structure/function, 251–252
 for dementia, 422
 development of, 257–258
 and dopamine theory, 250
 first-generation, 258
 for personality disorder, 453
 right to refuse, 476–478
 for schizophrenia, 257–261
 second-generation, 258–260
 side effects of, 258
- Antiseizure medications, 100, 141
- Antisocial behavior, 374–378, 441–444
- Antisocial personality disorder (APD), 429, 441–444
 in adoptees, 93
 clinical description of, 441
 comorbidities with, 432
 conduct disorder treatments and, 379
 DSM-5 criteria for, 442
 emotions with, 45
 etiology of, 443–444
 gender differences in, 45
 heritability of, 437
 inter-rater reliability for, 433
 key features of, 431
 maladaptive cognitions with, 452
 prevalence of, 432
 psychopathy vs., 441–442
- Antithesis, 454
- Anxiety, 152
 and ADHD, 369
 in adolescence, 385–389
 and alcohol consumption, 293
 and attention to threat, 166–167
 and autism spectrum disorder, 398
 in childhood, 385–389
 and conduct disorder, 374
 and depression, 128
 fear vs., 152
 and LSD, 286
 medications to reduce, 178–179
 in older adults, 410
 and personality disorders, 432
 and personality traits, 436
 and sexual dysfunction, 348
 and somatic symptom disorders, 227, 234
- Anxiety disorders, 151–180
 anxiety and fear in, 152
 autonomic nervous system in, 36
 and binge eating disorder, 317
 and bulimia nervosa, 313
 in childhood and adolescence, 385–388
 clinical description of, 153–160, 385–387
 comorbidity in, 64, 158–159
 and culture, 160–161
 defining, 152
 and depressive disorders, 118
 in DSM-5, 366
 ethnicity and prevalence of, 46
 etiology of, 387
 and gender, 160
 gender differences in, 46
 influences on, 168–174
 international prevalence of, 60, 61
 meta-analyses of, 110
 neuroscience approaches to, 38
 neurotransmitters involved in, 33
 and obsessive-compulsive related disorders, 188
 and personality disorders, 432
 and posttraumatic stress disorder, 200–201
 prevalence of, 91, 385
 risk factors for, 436–438
 and somatic symptom and related disorders, 222–223
 treatment of, 174–179, 387–388
- Anxiety Sensitivity Index (ASI), 172
- Anxiolytics, 178
- AOT (assisted outpatient treatment), 473
- APA. *See* American Psychiatric Association (APA)
- Apathy, 240, 413, 416
- APD. *See* Antisocial personality disorder (APD)
- Aphonia, 225
- ApoE $\epsilon 4$ allele, 418
- Applied behavior analysis, 393
- Appraisal, 20
- APS (attenuated psychosis syndrome), 244–245
- Archetypes, 18
- Aricept (donepezil), 422
- Aripiprazole (Abilify), 259, 402
- Arousal
 and anxiety/fear, 152
 biological, 339–340, 342–343
 in gender and sexuality, 338–339
 and paraphilic disorders, 351, 354–355
 physiological and sexual, 348
 sexual disorders involving, 342–343
- Arousal and reactivity symptoms (PTSD), 199, 386
- ASD. *See* Acute stress disorder; Autism spectrum disorder
- ASI (Anxiety Sensitivity Index), 172
- Asians and Asian Americans
 alcohol tolerance of, 289
 alcohol use disorders for, 271
 anxiety disorders for, 160
 cultural bias in assessment with, 80–81
 emotion, modulating, 103
 rates of psychological disorders for, 60
 tobacco use by, 274
- Asociality, 240
- Asperger, Hans, 397
- Asperger's disorder, 59, 397
- Asphyxiophilia, 357
- Assessment, 53–54, 68–82
 behavior, directly observing, 75
 clinical interviews for, 69–72
 cognitive tests, 74–75
 cultural and racial bias in, 80–82
 diagnosis, 57–68
 experience sampling, 76
 intelligence test, 74–75
 neurobiological, 77–80
 neuropsychological tests, 74–75
 personality tests, 72–74
 psychological, 68–77
 reliability in, 54–55
 self-report questionnaires, 76
 stress, 69–72
 validity in, 55–56
- Assimilation, cultural. *See* Acculturation
- Assisted outpatient treatment (AOT), 473
- Association studies. *See* Genome-wide association studies (GWAS)
- Asylums, 10–12
- Ataque de nervios, 7, 61, 201
- Atkins, Daryl, 469–470
- Atkins v. Virginia, 470
- Attachments, 398
- Attachment therapies, 100
- Attention
 cognitive science view of, 42
 and delirium, 424–425
 to internal vs. social cues, 169–170
 joint, 397, 402
 in somatic symptom and related disorders, 229–230
 to threat, 166–167
- Attention-deficit/hyperactivity disorder (ADHD), 366–373
 in adulthood, 369–370
 and binge eating disorder, 318
 bipolar disorder vs., 383–384
 brain and environmental influences, 370–371
 cause of, 370–371
 clinical descriptions of, 367–369
 comorbidity with, 368
 in DSM-5, 366, 368
 ethnicity and prevalence of, 46
 family factors in, 371
 gender differences in, 46
 genetic influences, 370
 neuroscience approaches to, 39
 ODD vs., 373
 prevalence of, 367–369
 prognosis of, 367–369
 psychological treatment for, 372–373
 sex differences, 369
 stimulant medications for, 372
 treatment of, 372
- Attenuated psychosis syndrome (APS), 244–245
- Attractiveness, 192, 330, 351, 446
- Attribution(s), 130
- Attributional style, 130, 382
- Auditory hallucinations, 46, 240
- Aurora, Colorado, 462, 472
- Australia, 256, 294, 316, 326
- Austria, 15
- Autism, 395–397
- Autism spectrum, 395–397
- Autism spectrum disorder (ASD), 395–402
 brief history of, 397
 causes of, 400–401
 clinical description of, 396–397
 communications deficits, 397
 comorbidity and, 398
 in DSM-5, 366
 and fragile X syndrome, 392
 history of, 396
 prevalence of, 398
 prognosis for children with, 399
 repetitive and ritualistic acts, 398
 social and emotional disturbances, 396–397
 Temple Grandin on, 399
 treatment of, 401–402
- Autistic aloneness, 397
- Autistic disorder, 397
- Autoimmune reactions, 63
- Autonomic nervous system (ANS), 36, 376
- Aversion therapy, 361
- Aversive feedback, 443
- Aversive parental behavior, 437

- Avoidance (avoidant behaviors), 212, 229
- Avoidance symptoms, PTSD, 199
- Avoidant personality disorder, 156, 449
- comorbidities for, 433–434
- defining symptoms for, 449
- heritability of, 437
- inter-rater reliability for, 433
- key features of, 431
- maladaptive cognitions with, 452
- prevalence of, 432
- test–retest stability for, 433
- Avoidant/restrictive food intake disorder, 309
- Avolition, 240, 264
- Awareness (of somatic symptoms), 228–231
- Axis I disorders, 58
- Axis II disorders, 59
- Axis III disorders, 59
- Axis IV disorders, 59
- Axis V disorders, 59
- B**
- BAC (blood alcohol concentration), 271
- Baltimore Longitudinal Study of Aging, 409
- Bariatric surgery, 323, 325
- Basal ganglia, 252, 291
- BA therapy. *See* Behavioral activation (BA) therapy
- BDD. *See* Body dysmorphic disorder
- Beck, Aaron, 42–43
- Bedlam, term, 10
- Behavior(s). *See also specific types*, e.g., Safety behaviors
- of adolescents with ADHD, 369
- direct observation of, 75
- nonobvious causes of, 18
- short-term effects of alcohol on, 271
- unconscious influences on, 18
- Behavioral activation (BA) therapy, 39, 136–137
- Behavioral assessment, 75
- Behavioral component of emotion, 44
- Behavioral couples therapy, 137
- Behavioral factors, in disorders, 168–174
- Behavioral inhibition, 165, 387
- Behavioral model, 190
- Behavioral research, 481
- Behavioral therapies/treatments. *See also* Cognitive behavioral therapy (CBT)
- for ADHD, 372
- for anxiety in children, 388
- for autism spectrum disorder, 401–402
- for dementia, 422–423
- influences from, 39
- for intellectual disability, 393–394
- for sexual dysfunctions, 351
- for somatic symptom and related disorders, 232–235
- Behavioral variant FTD, 419–420
- Behavioral view of exposure treatment, 175
- Behavioral weight-loss programs, 332
- Behavior genetics, 28
- correlational method in, 92–93
- of eating disorders, 319
- on schizophrenia, 246–248
- on substance use disorders, 289
- Behaviorism, 18–21
- Belgium, 61, 102
- Beliefs
- and anxiety disorders, 166
- in hoarding disorder, 192
- negative, 166, 169
- about sexuality, 336
- in treatment of bulimia nervosa, 330–331
- Belonging, sense of, 145
- Benzodiazepines, 38, 178–179, 271, 412
- Bethlehem (asylum), 10–11, 13
- BFI-2 (Big Five Inventory-2), 74, 80
- Bianchi, Ken, 220
- Biases
- attention, 166–167
- cognitive, 229, 453
- confirmation, 108
- cultural, 80–82
- information-processing, 129–130
- publication, 107, 109
- reporting, 340, 412
- Big data approaches to cognitive science, 41
- Big Five Inventory-2 (BFI-2), 74, 80
- Biggest Loser, The* (television series), 317
- Binge drinking, 267
- Binge eating disorder, 314–318
- cognitive behavioral views of, 322
- DSM-5 criteria for, 314
- medications for, 329
- psychological treatment for, 331–332
- Binges, 313–314
- Bini, Lucino, 14
- Biological approach, to
- psychological disorders, 9, 14–15
- Biological factors, in
- disorders, 117. *See also* Neurobiological influences
- Biological treatments, 14–15, 61–62, 138–141
- Bipolar disorders
- brain structures associated with, 125
- in childhood and adolescence, 380–383
- clinical descriptions of, 119–122
- epidemiology and consequences of, 121
- ethnicity and prevalence of, 46
- gender differences in, 46
- genetic factors in, 123
- prevalence of, 14
- lifetime prevalence rates, 91, 380
- living conditions for people with, 22
- neurobiological hypotheses of, 123
- and schizophrenia, 246, 247
- social and psychological factors in, 132
- treatment of, 137–138, 140–141
- Bipolar I disorder, 114, 119–120
- ADHD vs., 401
- brain structures involved in, 125
- epidemiology and consequences of, 121
- genetic influences in, 123
- and lithium, 140–141
- predictors for, 132
- prevalence of, 91
- reliability data, 66
- and reward sensitivity, 132
- Bipolar II disorder, 114, 120, 123
- Birth complications, schizophrenia and, 253
- Birth weight, ADHD and, 371
- Black, William, 13
- Bleuler, Eugen, 243
- Blindness, unexplained, 231
- Blood alcohol concentration (BAC), 271
- Blood flow, sexual response and, 339
- Blood oxygenation level dependent (BOLD) signal, 78
- Blood vessels, effect of cocaine on, 286
- Blunted affect, 241
- BMI. *See* Body mass index (BMI)
- Bodily cues, 165, 172, 218
- Body dysmorphic disorder (BDD)
- causes of, 192
- clinical description of, 185–186
- diagnosis of, 182
- prevalence of and comorbidity with, 188
- treatment of, 193–197
- Body image, 309–310, 321–323
- Body mass index (BMI), 309–310, 314, 321, 323–325
- Body Project, 332
- Body shame, 325
- Body weight, 271, 309–310, 313, 322, 325, 327, 330
- Boldness, 442
- BOLD (blood oxygenation level dependent) signal, 78
- Borderline personality disorder (BPD), 444–446
- and childhood sexual assault, 347
- clinical description of, 444–445
- empirically supported treatments for, 99
- etiology of, 445
- heritability of, 437
- inter-rater reliability for, 433
- key features, 431
- neurobiological factors, 445
- prevalence of, 410–411
- risk factors for, 438, 445
- test–retest stability for, 433
- BPD. *See* Borderline personality disorder (BPD)
- Brain, 34–35
- and ADHD, 370–371
- and auditory hallucinations, 240
- and autism spectrum disorder, 400–401
- and behavior relationships, 14
- and borderline personality disorder, 446
- and conduct disorder, 376
- connectivity in, 252–253
- and eating disorders, 320, 322
- environmental factors in
- development of, 253–254
- fear circuit in, 164
- and marijuana use, 278
- and methamphetamines, 285
- and mood disorders, 123–125
- and obsessive-compulsive disorders, 189
- and PTSD, 201–202
- reward pathways in, 289–291
- and schizophrenia, 250–252
- short-term effects of alcohol on, 271
- size of, autism spectrum disorder and, 400–401
- and somatic symptom-related disorders, 228–229
- structure and function of, 251–252
- valuing of delayed rewards in, 291–292
- Brain and environmental influences in ADHD, 370–371
- Brain imaging, 78–79
- Brain networks, 35
- Brain on Fire* (Cahalan), 63
- Brain stimulation, 79
- Breuer, Josef, 16
- Brief psychotic disorder, 243
- British Glossary of Mental Disorders*, 58
- British Medical Research Council, 481
- Broadcasting, thought, 239
- Broca, Paul, 14
- Broca's area, 240
- Buddhism, 367, 430
- Bulimia nervosa, 313–314
- binge eating disorder vs., 314, 318
- cognitive behavioral views of, 322–323
- cross-cultural studies of, 326–327
- empirically supported treatments for, 99
- genetic influences, 319
- medications for, 329
- neurobiological influences, 320–321
- personality influences on, 327–328
- psychological treatment for, 330–331
- Bullying, 163, 317, 374
- Buprenorphine (Suboxone), 282, 304
- Bupropion (Wellbutrin), 301
- Bush, Kathleen, 225

- C**
- Caffeine, 284
- Caffeine intoxication, 62
- Cahalan, Susannah, 63
- California, 7, 14, 75, 262, 274, 276, 303, 369, 417, 468, 473–474, 478
- California Verbal Learning Test, 75
- Callous and unemotional traits, 374, 376
- Cambodia, 61
- Canada, 217, 256, 326
- Cannabinoid brain receptors, 278
- Cannabis. *See* Marijuana
- Capital punishment, 469–470
- Carbon dioxide, panic attacks and, 172
- Cardiovascular disease, 121, 346, 416
- Cardiovascular health, 422
- Caregivers, of people with dementia, 423
- Carlson, Elizabeth, 219
- Carpal tunnel syndrome, 225
- Case studies, 85–86
- Catastrophic misinterpretation, of bodily cues, 172
- Catatonia, 242
- Categorical classification, 65–66
- Catharsis, 16
- Cathartic method, 16
- CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness), 259
- CAT scan. *See* CT scan
- Caucasians, 326. *See also* European Americans
- Caudate nucleus, 189
- Causality, 90
- CB1 receptors, 278
- CBSST (cognitive-behavioral social skills training), 264
- CBT. *See* Cognitive behavioral therapy (CBT)
- CBT-guided self-help (CBT-gsh), 331
- CDC. *See* Centers for Disease Control and Prevention
- Celexa (citalopram), 139
- Center Cannot Hold, The* (Saks), 262
- Center for Nutrition Policy and Promotion, 316
- Centers for Disease Control and Prevention (CDC), 282, 369, 383, 414
- Cerebellum, 35, 400, 417
- Cerebral hemispheres, 34
- Cerletti, Ugo, 14
- Chance, 89
- Chantix (varenicline), 301
- Charcot, Jean-Martin, 15–16
- Charpentier, Paul, 258
- CHD (coronary heart disease), 273
- Childhood abuse. *See also* Childhood sexual abuse (CSA)
- and dissociative disorders, 216, 219
- and paraphilias, 354
- and personality disorders, 438, 445–446
- Childhood adversity
- and depression, 127–128, 380
- and personality disorders, 437, 443, 445
- Childhood disorders, 365–403.
- See also under* Children
- anxiety, 385–388
- attention-deficit/hyperactivity disorder, 366–373
- autism spectrum disorder, 395–402
- bipolar disorder, 383–384
- classification and diagnosis of, 366
- conduct disorder, 373–380
- controversy in diagnosis/treatment of, 383–384
- depression, 380–389
- externalizing disorders, 366–380
- intellectual disability, 389–395
- internalizing disorders, 380–389
- specific learning disorder, 389–395
- Childhood onset fluency disorder (stuttering), 390
- Childhood sexual abuse (CSA), 117, 206, 216, 347. *See also* Pedophilic disorder
- Children
- effects of secondhand smoke on, 275
- exposure to caffeine, 284
- and factitious disorder of parents, 226
- obesity in, 315–318
- Children in the Community Study, 439, 443, 445
- China, 45, 61, 102, 116, 135, 294, 301, 325
- Chlorpromazine (Thorazine), 258, 259, 405
- Cholesterol, 418, 421
- Cholinesterase inhibitors, 422
- Chromosomal abnormalities, 392
- Cialis (tadalafil), 352
- Cigarettes, 268, 295, 304–305. *See also* E-cigarettes
- Cigarette smoking
- ADHD and maternal, 371
- and emotion regulation, 292–293
- genetic influences in, 289
- and neurobiology of craving, 290–291
- prevalence and health consequences of, 273–275
- prevention of, 305
- in social settings, 295
- treatments for, 300–301
- in U.S. population, 268
- Ciguatera, 225
- Circadian rhythms and sleep in depression, 127
- Cirrhosis, liver, 272, 412
- CISD (critical incident stress debriefing), 207
- Citalopram (Celexa), 139
- Civil commitment, 470–479
- civil liberties, 477–479
- current insanity pleas, 462–463
- defined, 471
- deinstitutionalization, 473–474, 477–479
- duty to warn and protect, 473–474
- gun violence, mental illness in, 472–473
- insanity defense, 459–461
- least restrictive alternative, 475
- prediction of dangerousness, 472–473
- preventive detention, 471–472
- rights of people with psychological disorders, 475–479
- right to refuse treatment, 476–477
- right to treatment, 475–476
- Civil liberties, 477–479
- Classical conditioning, 19–20, 39–40, 85, 161–162, 168, 172, 202, 443
- Classroom management, ADHD and, 372
- “Clear and convincing evidence”, 461
- Cleckley, Hervey, 441
- Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 259
- Clinical high-risk studies, 245, 256
- Clinical interviews, 69–72, 76, 432
- Clinical psychologists, 23–24
- Clinical significance, 90
- Clock genes, 127
- Clomipramine (Anafranil), 194
- Close, Glenn, 5
- Clozapine (Clozaril), 259
- Cluster A personality disorders, 431, 439
- Cluster B personality disorders, 431, 439
- Cluster C personality disorders, 431, 439
- CNVs. *See* Copy number variations (CNVs)
- Coal gas, 148
- Cocaine, 285–286
- and abstinence, 302
- cravings for, 290–291
- drug replacements for, 302
- and ideal affect, 45
- marijuana as gateway drug for, 277
- positive emotion and use of, 294
- prevalence of use of, 268
- psychological treatments for use of, 302–305
- stimulant medication use and, 383–384
- young people’s use of, 277
- Cocaine Anonymous, 297
- Coca plant, 286
- Codeine, 280
- Code of Ethics* (APA), 480
- Coercive sexual behavior, 359
- Coffee, 284
- Cognition, 20–21, 40–41
- Cognitive behavioral factors, in disorders, 229–231, 321–323
- Cognitive behavioral influences, 39–44
- behaviorism, influence on, 40–41
- cognitive behavior therapy, 42
- cognitive science, 40–41
- evaluating, 42–43
- self-esteem and narcissism in, 470
- unconscious, role of, 41–42
- Cognitive behavioral models, 189, 229–231
- Cognitive-behavioral social skills training (CBSST), 264
- Cognitive behavioral therapy (CBT), 42
- for anxiety disorders, 175–178
- Beck’s cognitive therapy, 42
- CBT-guided self-help, 331
- for childhood and adolescent anxiety, 387–388
- for childhood and adolescent depression, 382–385
- for drug use disorder, 302–305
- for eating disorders, 329–332
- for hoarding disorder, 196–197
- internet-based, 206–207
- for obsessive-compulsive disorder, 190–192
- for schizophrenia, 264
- for somatic symptom and related disorders, 232–235
- Cognitive behavioral treatments, 361, 453
- Cognitive biases, 42, 229
- Cognitive distortions, 264, 330, 431
- Cognitive distraction, 292–293
- Cognitive factors, in disorders, 166–167, 169–170, 172–173
- Cognitive functioning, 278, 391, 407, 418
- Cognitive models, 190–192
- Cognitive processing therapy, 99, 206
- Cognitive reserve, 418
- Cognitive restructuring, 42, 135
- Cognitive science, 40–41
- Cognitive theories, 129–131
- Cognitive therapy (CT)
- for bipolar disorder, 137
- for depression, 134–136
- Internet-based, 136
- for major depressive disorder, 134–136
- negative thought in, 136
- for obsessive-compulsive disorder, 194
- for personality disorders, 453
- for PTSD, 206
- for somatic symptom and related disorders, 232
- and suicidality, 146
- Cognitive training, 419, 423
- Cognitive treatments, 394
- Cognitive view of exposure treatment, 175
- Cohort effects, 408, 412
- Collective unconscious, 18
- Collyer brothers, 187
- Colombia, 59–60, 102
- Colorado, 276, 462
- Combined specifier, ADHD, 368

- Comfort food, 317
 Commitment, 470–471. *See also*
 Civil commitment; Criminal
 commitment
 Communication deficits, 397
 Communication disorders, 366,
 390
 Community-based care, 265
 Community-based prevention
 programs, 148
 Community treatment, 477
 Comorbidity, 62. *See also specific*
 disorders
 Competency to stand trial,
 464–468
 Complex PTSD, 199
 Complex regional pain syndrome,
 224
 Compulsions, 69, 70, 182–183. *See*
 also Obsessive-compulsive
 disorder (OCD)
 defined, 184
 foci, 185
 Computer-assisted instruction
 (intellectual disability), 394
 Computerized training programs,
 423
 Concerta, 372
 Concordance, 92
 Conditioned response (CR),
 19. *See also* Classical
 conditioning
 Conditioned stimulus (CS),
 19. *See also* Classical
 conditioning
 Conditioning
 classical, 19–20, 40, 85, 161–
 162, 168, 172, 202
 fear, 162–163
 interoceptive, 172
 operant, 20, 39–40, 162, 169,
 202, 393
 in social anxiety disorder, 169
 for specific phobias, 168
 two-factor model of, 162
 Conduct disorder, 373–379
 and ADHD, 368
 and antisocial personality
 disorder, 441
 and binge eating disorder, 318
 and bulimia nervosa, 314
 causes of, 375–377
 clinical description of, 374
 comorbidity with and course of,
 374–375
 and posttraumatic stress
 disorder, 200
 prevalence of, 375
 prevention of, 379
 prognosis for children with, 375
 treatment of, 377–379
 Conduct Problems Prevention
 Research Group (CPRG),
 379
 Confidentiality, 482
 Confirmation bias, 108
 Confounds, 90
 Connectivity, 35, 252–253
 Constitution, U.S., 458
 Construct validity, 55, 79
 Consummatory pleasure, 240
 Contamination, fear of, 190
 Content validity. *See* Validity
 Contingency management
 therapy, 302, 304
 Contrast avoidance model, 173
 Control groups, 86, 94, 100
 Controlled drinking, 299
 Control, perceived lack of, 166
 Coping, 203–204
 Coping Cat, 387–388
 Copy number variations (CNVs),
 30, 249–250
 Coronary heart disease (CHD),
 273
 Corporate success, psychopathy
 and, 442
 Correlates, 91
 Correlation, 87
 Correlational method, 86–93, 105
 behavior genetics research
 with, 92–93
 epidemiologic research with,
 91–92
 measuring correlation, 88
 problems of causality in, 90
 and statistical/clinical
 significance, 88–90
 Correlation coefficient, 88
 Cortico-striatal-thalamic-cortical
 (CSTC) loop, 189
 Corticotropin-releasing factor
 (CRF), 37
 Cortisol, 37
 Cosmetic surgery, 407
 Counseling psychologists, 24
 Couples therapy, 47, 99, 137, 298,
 350
 CPA (cyproterone acetate), 361
 CPRG (Conduct Problems
 Prevention Research
 Group), 379
 CR. *See* Conditioned response
 (CR)
 Crack, 285
 Cravings, 290–291, 320
Creating Hysteria (Acocella), 219
 Creativity, mood disorders and,
 121–122
 CRF (corticotropin-releasing
 factor), 37
 Crime, mental illness and, 459
 Criminal commitment, 458–464
 defined, 458
 and insanity defense, 459
 landmark cases and laws,
 459–461
 Criterion validity. *See* Validity
 Critical incident stress debriefing
 (CISD), 207
 Criticism, body image and, 321
 Cross-cultural studies (eating
 disorders), 32–327
 Cross-fostering, 93
 Cross-gender behavior, 338
 Cross-national studies (substance
 use), 294
 Cross-sectional design, 90
 Crystal meth, 284
 CS. *See* Conditioned stimulus
 CSA. *See* Childhood sexual abuse
 CT. *See* Cognitive therapy (CT)
 CT (CAT) scan, 63, 223
 Cultural bias, 80–82
 Cultural competence, 103
 Cultural concepts of distress, 60
 Cultural influences
 in anxiety disorders, 160–161
 in body dysmorphic disorder,
 186
 in functional neurological
 symptom disorder, 231–232
 in internalizing/externalizing
 behaviors, 383
 in obsessive-compulsive
 disorder, 366
 in personality disorders, 431
 in posttraumatic stress disorder,
 201
 in sexual dysfunction, 342, 348
 in treatment outcome studies,
 103
 Culture. *See also* Ethnicity
 and alcohol consumption,
 294–295
 and DSM classifications, 59–62
 in expressed emotion, 261–262
 and gender differences in
 sexuality, 338
 and sexual norms, 336–340
 Cyclothymic disorder
 (cyclothymia), 120–121
 CYP2A6 gene, 289
 Cyproterone acetate (CPA,
 Gyrostat), 361
 Cytokines, 38, 125–126
- D**
 Dadas, Albert, 217
 Dahmer, Jeffrey, 463
 Daily report cards (DRCs), 373
 Daily thought monitoring, 135
 Danes, Clare, 399
 Dangerousness, 471–475
 Danish Civil Registration System,
 246
 Dapoxetine, 351
 DARE programs, 100
 Dark Ages, 9–10
 Dark Knight, The, 462
 Darwin, Charles, 223
 DAS (Dysfunctional Attitudes
 Scale), 129
 Daytop Village, 302
 DBT. *See* Dialectical behavior
 therapy (DBT)
 Death, 312–314
 Decentered perspective, 136
 Decision-making,
 methamphetamine use and,
 285
 Declaration of Helsinki, 481
 Deep brain stimulation, 197
 Defense mechanisms, 17
 Defining symptoms
 agoraphobia, 158
 anorexia nervosa, 310
 antisocial personality disorder,
 441
 attention-deficit/hyperactivity
 disorder, 368
 autism spectrum disorder, 398
 avoidant personality disorder,
 450
 binge eating disorder, 317
 body dysmorphic disorder, 186
 borderline personality disorder,
 445
 bulimia nervosa, 313
 conduct disorder, 374
 cyclothymic disorder, 120
 delayed ejaculation, 343
 delirium, 425
 dementia, 414
 dependent personality disorder,
 449
 depersonalization/derealization
 disorder, 213
 dissociative amnesia, 214
 dissociative identity disorder,
 217
 erectile disorder, 342
 exhibitionistic disorder, 356
 factitious disorder, 227
 female orgasmic disorder, 343
 female sexual interest/arousal
 disorder, 342
 frotteuristic disorder, 356
 gambling disorder, 269
 generalized anxiety disorder,
 159
 general personality disorder,
 431
 genito-pelvic pain/penetration
 disorder, 344–345
 histrionic personality disorder,
 441
 hoarding disorder, 187
 illness anxiety disorder, 224
 major depressive disorder, 115
 male hypoactive sexual desire
 disorder, 342
 manic/hypomanic episodes,
 119
 mild cognitive impairment, 414
 narcissistic personality disorder,
 447
 obsessive-compulsive disorder,
 183
 obsessive-compulsive
 personality disorder, 450
 panic disorder, 157
 paranoid personality disorder,
 439
 pedophilic disorder, 354
 persistent depressive disorder,
 116
 posttraumatic stress disorder,
 200
 premature ejaculation, 343
 schizoid personality disorder,
 439
 schizophrenia, 238
 schizotypal personality
 disorder, 440
 separation anxiety disorder,
 386
 sexual masochism disorder, 357
 sexual sadism disorder, 357
 social anxiety disorder, 156
 somatic symptom disorder, 224
 specific phobias, 155
 substance use disorder, 268
 voyeuristic disorder, 355
 Deinstitutionalization, 12,
 477–479
 Delayed ejaculation, 343
 Delayed ejaculation disorder,
 343
 Delayed rewards, value of
 immediate vs., 291–292
 Deletions, 30

- Delirium, and activity, 425
 Delirium tremens (DTs), 270
 Delusional disorders, 243
 Delusions
 and dementia, 413–414
 in schizophrenia, 238–239
 in schizotypal personality disorder, 440
 violence linked to, 471
 Dementia, 413–424
 and Alzheimer's disease, 415–418
 defined, 413
 delirium vs., 425
 frontotemporal, 419–420
 Huntington's disease, 421
 with Lewy bodies, 421
 prevalence of, 415
 treatment of, 421–423
 vascular, 420–421
 Dementia praecox, 58, 243
 Dementia with Lewy bodies (DLB), 421
 Dendritic spines, 252
 Denial, 17
 Denmark, 246, 325
 De novo mutations, 30
 Dependent personality disorder, 452
 in Alternative DSM-5 model, 434
 inter-rater reliability for, 433
 key features of, 431
 prevalence of, 432
 Dependent variables, 93
 Depersonalization, 157, 212–213
 Depersonalization/derealization disorder, 212–213
 causes of, 218
 Depo-Provera (medroxyprogesterone), 361
 Depression. *See also* Major depressive disorder (MDD)
 and ADHD, 369
 in adolescence and childhood, 380–388
 and Alzheimer's disease, 416
 analogue experiments with, 105
 and anorexia nervosa, 312
 and anxiety/anxiety disorders, 128, 159
 in bipolar disorder, 132
 and borderline personality disorder, 444
 and bulimia nervosa, 313
 and cardiovascular disease, 118
 causes of, 381–382
 circadian rhythms and sleep, 126–127
 clinical description, 461
 cognitive therapy for, 42
 comorbidities, 57, 380–381
 and conduct disorder, 373–374
 cultural differences in, 116–118
 and dementia, 413, 419
 electroconvulsive therapy for, 14, 139
 emotions with, 44
 empirically supported treatments for, 99
 ethnicity and prevalence of, 46
 gender differences in, 45, 46, 117
 heritability of, 14
 neural regions associated with, 114
 and neuroticism, 165
 and obsessive-compulsive related disorders, 188
 in older adults, 410
 and personality disorders, 432
 and personality traits, 435
 placebo effect for treatments of, 101
 prevalence, 380
 psychological factors on, 128–131
 psychological treatment of, 134–137
 with psychotic features, 471
 and sexual dysfunction, 348
 social factors on, 127–128
 and somatic symptom disorders, 229, 234
 and suicide, 145
 transcranial magnetic stimulation for, 140
 treatment of, 382–385
 Depressive disorders
 clinical descriptions of, 114–118
 epidemiology and consequences of, 116–118
 medications for, 138–139
 and somatic symptom and related disorders, 222
 Depressive symptoms, older adults with, 412
 Derailment, 242
 Derealization, 157, 211–212. *See also* Depersonalization/derealization disorder
 Detachment, 435
 Detoxification, 297, 302
 Developmental coordination disorder, 390
 Developmental factors (schizophrenia), 255–256
 Developmental psychopathology, 366
 Deviant peers, affiliation with, 377
 Dhat syndrome, 160
 Diagnosis(-es), 53–54
 of children, 383–384
 correlational studies with, 86–87
 cultural considerations in, 59–62
 with DSM-5, 57–68
 general criticisms of, 67–68
 history of, 58–59
 importance of, 53
 multiaxial, 58–59
 number of, 62–63
 organizing, by cause, 59
 of public figures, 480
 reliability in, 54–55
 U.S. lifetime prevalence rates for, 91
 validity in, 55–56
Diagnostic and Statistical Manual of Mental Disorders (DSM), 59–68
 criticisms of, 62–67
 diagnostic criteria of, 242–243.
 See also specific disorders
 DSM-II, 57–58, 66, 384, 397
 DSM-III, 58, 66, 217, 397
 DSM-III-R, 58
 DSM-IV, 58–59, 62, 91, 110, 397
 DSM-5, 6, 57, 60, 117, 434
 DSM-IV-TR, 58–59, 61, 223, 227, 397, 434
 ethnic and cultural considerations with, 59–62
 organization of diagnoses, 59
 Dialectical behavior therapy (DBT), 93, 147, 454
 Dialectics, 454
 DID. *See* Dissociative identity disorder (DID)
 Dieting, 323
 Digit Span, 75
 Dimensional diagnostic system, 65
 Directed masturbation, 351
 Directionality problem, 90
 Direct observation, 75
 Disability, 7. *See also* Intellectual disability
 Disconnection syndrome, 252
 Disinhibition, 294, 435
 Disorganized behavior, 242–243
 Disorganized speech, 238, 241–242
 Disorganized symptoms, 239, 241–243
 Disorientation, 416
 Displacement, 17
 Disruptive, impulse control, and conduct disorders, 60, 366
 Disruptive mood dysregulation disorder (DMDD), 114, 383
 Dissemination, 104
 Dissociation, 203–204, 211–212
 Dissociative amnesia, 211, 214–215
 Dissociative disorders, 211–221
 causes of, 218–220
 clinical descriptions of, 211–218
 depersonalization/derealization disorder, 212–213
 diagnoses of, 211–212
 dissociative amnesia, 214–215
 dissociative identity disorder, 215–217
 epidemiology of, 217
 and memory, 216
 treatment of, 221
 Dissociative fugue. *See* Fugue subtype
 Dissociative identity disorder (DID), 215–217
 causes of, 218–220
 and childhood sexual assault, 347
 clinical description of, 215–217
 diagnosis of, 223
 epidemiology of, 217
 and insanity defense, 468
 living conditions for people with, 22
 treatment of, 221
 Dissociative identity disorder-oriented therapy, 100
 Distraction, alcohol/nicotine and, 292–293
 Distress
 cultural concepts of, 60
 cultural differences in expressing, 160–161
 marital, 136, 158
 personal, 7
 from phobias, 7
 relationship, 47, 99, 341
 over somatic symptoms, 229–231
 Disulfiram (Antabuse), 299, 300
 Dix, Dorothea, 11
 Dizygotic (DZ) twins, 93. *See also* Twin studies
 DLB (dementia with Lewy bodies), 421
 DMDD. *See* Disruptive mood dysregulation disorder (DMDD)
 DNA, 27
 Dodge, Kenneth, 376
 Donaldson, Kenneth, 475–476
 Donepezil (Aricept), 422
 Dopamine, 33
 and ADHD, 370
 and alcohol, 271
 and amphetamines, 285
 and cocaine, 286
 and eating disorders, 320–321
 and methamphetamine use, 285
 and schizophrenia, 250–251
 and substance use disorder, 289–290
 Dopamine theory, 250
 Dorsal striatum, 320
 Dorsolateral prefrontal cortex, 123–125
 Double-blind procedures, 101
 Down Syndrome (trisomy 21), 392
 DRCs (daily report cards), 373
 Dreams, dementia with Lewy bodies and, 421
 Drink, measuring one, 271
 Driving, 272, 282
 Drug abuse, 91, 100, 411
 Drug courts, 303
 Drug Enforcement Agency, 304
 Drugs. *See also* Medication(s) and ADHD medications, 383–384
 patients' understanding of, 481
 prevalence of use, 267–268
 Drug use disorders, 280–288, 302–305. *See also* Substance use disorders
 DSM. *See* *Diagnostic and Statistical Manual of Mental Disorders (DSM)*
 DTs (delirium tremens), 270
 Dunham, Lena, 188
 Dunst, Kirsten, 116
 Durham test, 459–460
Durham v. United States, 460
 Duty to warn and protect, 474
 Dyscalculia, 390
 Dysfunction, 7
 Dysfunctional Attitudes Scale (DAS), 129
 Dyslexia, 389–390
 Dysthymia. *See* Persistent depressive disorder

- DZ (dizygotic) twins, 93. *See also* Twin studies
- E**
- Early ejaculation. *See* Premature ejaculation
- Early infantile autism, 397
- Early-intervention programs, 393
- East Asian cultures, 45, 81
- Eating disorders, 308–332. *See also* Obesity
- anorexia nervosa, 309–312
 - binge eating disorder, 314–318
 - bulimia nervosa, 313–314
 - and childhood sexual assault, 347
 - clinical descriptions of, 309–318
 - cognitive behavioral factors in, 321–323
 - etiology of, 319–328
 - families of individuals with, 328
 - genetic influences, 319
 - meta-analyses of, 110
 - neurobiological influences, 320–321
 - and obesity, 315–317
 - and personality, 327–328
 - preventive interventions for, 332
 - sociocultural influences, 323–327
 - treatment of, 329–332
- Eating Disorders Inventory, 310–311
- eBodyProject, 332
- Echolia, 397
- E-cigarettes (electronic cigarettes), 276–277, 301
- Ecological momentary assessment (EMA), 76, 322–323
- Ecstasy, 286–288
- ECT. *See* Electroconvulsive therapy
- Education, 4–5, 271
- EE. *See* Expressed emotion
- Effect, law of, 20
- Effective connectivity, 35
- Effectiveness studies, 104
- Effect size (meta-analysis), 110
- Efficacy, 104
- Ego, 16
- Eighth Amendment, 469
- Elder abuse, 407
- Electroconvulsive therapy (ECT), 14, 138–140
- Electronic cigarettes (e-cigarettes), 276–277, 301
- Eli Lilly, 260
- EMA. *See* Ecological momentary assessment
- EMDR (eye movement desensitization and reprocessing), 206
- Emergency commitment, 471
- Emotion(s)
- of anxiety and fear, 152
 - and autism spectrum disorder, 397, 401
 - and generalized anxiety disorder, 173
 - and mood disorders, 123–125
 - and psychological disorders, 44–45
 - and psychopathy, 441–443
 - regulation of, 202, 206, 287, 292–293, 358, 383, 407, 429, 454
- Emotional attachment, hoarding disorder and, 192
- Emotional disturbances, ASD and, 395–397
- Emotional intimacy, 407
- Emotional overinvolvement, 255–257
- Empathy, 444
- Empirically supported treatments (ESTs), 99, 104, 109
- Employment, 264
- Encephalitis, 393
- England, 10, 14, 325. *See also* United Kingdom
- Entorhinal cortex, 417
- Environmental tobacco smoke (ETS), 275
- Environment and environmental factors. *See also* Sociocultural influences
- in ADHD, 371
 - in autism spectrum disorder, 400
 - in brain development, 253–254
 - and intellectual disability, 393
 - nonshared, 27
 - and obesity, 316
 - in personality disorders, 437–438
 - shared, 27
 - in substance use disorders, 289
- Epidemiological studies, 317
- Epidemiology, 91–92
- Epigenetics, 31
- Epilepsy, 14–15
- Episodic disorders, 115
- Erectile disorder, 341
- Erectile dysfunction, 343, 348
- Erectile problems, for older adults, 410
- ERP. *See* Exposure and response prevention (ERP)
- Esketamine (Spravato), 139
- Eskimos, 45
- ESTs. *See* Empirically supported treatments (ESTs)
- Estradiol, 346
- Ethical issues, 478–483. *See also* Legal issues
- confidentiality, 482
 - informed consent, 481–482
 - privileged communication, 482
 - and restraints on research, 480–481
- Ethnicity
- and alcohol use disorders, 271
 - and dementia, 415
 - and eating disorders, 327
 - and mental health treatment, 260
 - and psychopathology, 45
 - and schizophrenia, 255
 - and tobacco use, 274
 - and treatment outcome studies, 103
- ETS (environmental tobacco smoke), 275
- Eugenics, 14
- Europe, 10, 15, 61, 110, 217, 407
- European Americans, 81, 263. *See also* Whites
- Excess, sexual behavior in, 336
- Executive functioning, 256, 369
- Exelon (rivastigmine), 422
- Exercise, 415, 418
- Exhaustion, 71
- Exhibitionistic disorder, 353, 356
- Exorcism, 8
- Expectancies, about alcohol and drug effects, 291
- Experience component of emotion, 44
- Experiments, 86, 93–97
- analogue, 105–107
 - correlational studies vs., 86–87
 - experimental design, basic features of, 93–94
 - external validity in, 94
 - internal validity in, 94
 - single-case, 94–96
 - treatment outcome research, 98
- Experimental effect, 94
- Explicit memory, 220
- Exposure, 40, 194
- Exposure and response prevention (ERP), 194
- for body dysmorphic disorder, 195
 - for bulimia nervosa, 331–332
 - with children, 388
 - for hoarding disorder, 195–196
 - internet-based, 195
 - for OCD, 194
- Exposure hierarchy, 175, 176, 205
- Exposure treatment (exposure therapy), 175–178, 205–207
- Expressed emotion (EE), 128, 261–262
- Expression domain, 241
- Expressive-experiential therapies, 100
- Externalizing behavior problems, 47, 367
- Externalizing disorders, 31, 64, 366. *See also* Attention-deficit/hyperactivity disorder (ADHD); Conduct disorder
- External validity, 94
- Extinction, 19, 163, 165, 167, 175, 177
- Extrapyramidal side effects, 258
- Eye movements, of children with ASD, 397
- Eye movement desensitization and reprocessing (EMDR), 206
- F**
- Facilitated communication, 100
- Factitious disorder, 222
- Factitious disorder imposed on another, 226
- Fact magazine, 480
- Familial high-risk studies, 246–247
- Family-based therapy (FBT), 329
- Family CBT, 388
- Family checklist (FCU) treatment, 377
- Family-focused treatment (FFT), 48
- Family interventions (conduct disorder), 377–378
- Family method, 92
- Family psychoeducation, 99, 263, 388
- Family-related factors, in disorders, 261–263, 371
- Family studies of autism spectrum disorder, 400
- of schizophrenia, 246–247, 261–263
 - of schizotypal personality disorder, 440
- Family support, 4–5
- Family therapy, 47
- for anorexia nervosa, 329–330
 - for bulimia nervosa, 331
 - for hoarding disorder, 197
 - for schizophrenia, 263
 - for somatic symptom and related disorders, 234
- FAS (fetal alcohol syndrome), 272
- Fast Track, 379
- FBT (family-based therapy), 329
- FCU (family checklist) treatment, 377
- FDA. *See* Food and Drug Administration
- Fear(s). *See also* Phobia(s)
- in anorexia nervosa, 309, 321, 324
 - anxiety vs., 152, 383
 - of contamination, 183
 - of impending illness, 230
- Fear circuit, 164
- Fear conditioning (anxiety disorders), 162–163
- Fearlessness, in psychopathy, 443
- Fear response, extinction of, 175
- Feeding and eating disorders, 366
- Female orgasmic disorder, 341, 343–344, 348, 350–351
- Female sexual interest/arousal disorder, 342–343
- Fentanyl, 280–282
- Fetal alcohol syndrome (FAS), 272
- Fetishistic disorder, 353
- fetlife.com, 353
- FFT. *See* Family-focused treatment (FFT)
- Fifty Shades of Gray* (James), 353
- Fight-or-flight reaction, 152
- Finland, 289
- First-degree relatives, 92
- First-generation antipsychotics, 258
- 5HTTLPR gene, 376
- Five-factor model, 435
- Flashbacks, 286
- Flight of ideas, 119
- Flint, Michigan, 393
- Florida Supreme Court, 470
- Fluoxetine (Prozac), 38, 64, 138, 329, 332, 382–383
- fMRI gene, 392
- fMRI. *See* Functional magnetic resonance imaging
- Fluphenazine, 259

- Food, 308, 315–317
 Food additives, 371
 Food and Drug Administration (FDA), 79, 139, 194, 197, 205, 275, 297, 305, 316, 351, 372, 383
 Food phobias, 95
 Forced medication, 467
 Forensic hospitals, 458, 462–463, 466
 Foreseeable victims, protection for, 474
 Formal commitment, 470–473
 Formal thought disorder, 241
 Fragile X syndrome, 392
 France, 15, 61, 102, 116, 217, 235, 294
 Freud, Sigmund, 16–19, 41, 214, 225
 Friends' Asylum, 11
 Frontal cortex, 35, 123, 240, 252, 279, 290, 371, 401, 417
 Frontal lobes, 14, 371
 Fronto-striatal circuits, 189
 Frontotemporal dementia (FTD), 419–420
 Frotteuristic disorder, 353, 356
 Fugue subtype, 211, 214
 Functional connectivity, 35
 Functional magnetic resonance imaging (fMRI), 35, 78, 203, 229, 253, 271, 279, 285, 291–292, 320, 397, 401, 448
 Functional neurological symptom disorder, 211, 222, 224–227, 231–232
 treatment of, 234–235
 Fusiform gyrus, 397
- G**
 GABA. *See* Gamma-aminobutyric acid (GABA)
 GABA receptors, 271
 GAD. *See* Generalized anxiety disorder (GAD)
 Galen, 9
 Galton, Francis, 14
 Gambling disorder, 268–269
 Gamma-aminobutyric acid (GABA), 33, 162, 271
 GAS (general adaptation syndrome), 71
 Gassner, Johann, 15
 Gateway drug, marijuana as, 277
 Gauguin, Paul, 326
 GBMI. *See* Guilty but mentally ill (GBMI)
 Genain quadruplets, 247
 Gender
 and ADHD, 369
 and alcohol consumption, 271, 272
 and alcohol use disorders, 271, 272
 and anxiety/anxiety disorders, 160, 385
 and body dysmorphic disorder, 188
 and depression, 117
 and eating disorders, 312, 317
 and hoarding disorder, 187
 and ideal body weight, 323–325
 and marijuana use, 276–277
 and methamphetamine use, 285
 and obsessive-compulsive disorder, 188
 and ODD/conduct disorder, 373
 and opioid use, 282
 and paraphilic disorders, 353–354
 and psychopathology, 45
 and PTSD, 201
 and rape, 359
 and rumination, 130
 and schizophrenia, 257
 and sexual dysfunction, 340–341
 and sexuality, 338–339
 and suicide, 144
 and tobacco use, 273–274
 Gender dysphoria, 336, 338
 Gender identity, 338
 Genes, 27–30, 249
 Gene–environment interactions, 30–31, 93, 289, 376, 377
 Gene expression, 27
 General adaptation syndrome (GAS), 71
 General anxiety, 388
 Generalized anxiety disorder (GAD), 158
 in adolescents, 380
 clinical description of, 158–159
 empirically supported treatments for, 99
 influences on, 173
 in late life, 411
 prevalence of, 91, 380
 psychological treatment of, 178
 General paresis, 14
 General personality disorder, 431
 Genetics, 14
 Genetic influences
 in ADHD, 370
 in antisocial personality disorder, 443
 in anxiety disorders, 164, 387
 in autism spectrum disorder, 400
 in borderline personality disorder, 446
 in conduct disorder, 375–376
 in depression during childhood and adolescence, 381–382
 in eating disorders, 319
 in intellectual disability, 392
 in mood disorders, 123
 in obesity, 316
 in personality disorders, 436–438
 of psychopathy, 26–32
 in schizophrenia, 246–250
 in substance use disorders, 288–289
 Genetic vulnerability, 164
 Genito-pelvic pain/penetration disorder, 341, 344, 351
 Genome-wide association studies (GWAS), 30
 of Alzheimer's disease, 418
 of autism spectrum disorder, 400
 of eating disorders, 319
 of schizophrenia, 248–249
 of substance use disorders, 289
 Genotype, 28
 Geodon (ziprasidone), 259
 Germany, 61, 102, 295
 Germ theory of disease, 21
 Ghost sickness, 61
 Glenn, John, 407
 Global attributions, 130
 Glove anesthesia, 225
 Glutamate, 251
 Goals, pursuit of, 443–444
 Golden Gate Bridge, 148
 Goldwater, Barry, 480
Gone with the Wind (film), 359
 Go/no-go task, 291
 Google, 38, 41
 Grandin, Temple, 399
 Grandiose delusions, 239
 Gray matter, 34, 273
 Greenland, 160
 Grief, unresolved, 48
 Grief counseling, 100
 Group therapy, 388, 453
 Guided imagery, 216
 Guided self-change, 299
 Guided self-help CBT, 331
Guidelines for Translating and Adapting Tests (ITC), 80
 Guilty but mentally ill (GBMI), 463
 Gum, nicotine, 301
 Gun ownership, suicide rates and, 144
 GWAS. *See* Genome-wide association studies (GWAS)
- H**
 Haldol (haloperidol), 259
 Hall, Freddie Lee, 470
 Hallucinations, 240, 270, 416
 Hallucinogens, 268, 277, 286–288
 Hallucinogen persisting perception disorder, 286
 Haloperidol (Haldol), 259
 Harmful therapies, 100
 Hartford Retreat, 11
 Harvard School of Public Health, 295
 HCR-20 (Historical-Clinical-Risk Management-20), 472
 Head Start program, 378
 Health anxiety, 229
 Health care system interventions, 232
 Healthy Weight intervention, 332
 Heart rate, antisocial behavior and, 376–377
 Henry VIII, 10
 Here's the Deal (Mandel), 183
 Heritability, 27, 86
 Heroin, 280
 effects of, 280
 and ideal affect, 45
 marijuana as gateway drug for, 277
 in medications, 282–283
 prevalence of use of, 268
 treatment for use of, 302
 Heterogeneous, term, 246
 High-risk method, 90
Hikikomori, 61
 Hillside strangler, 221
 Hinckley, John, Jr., 460–461
 Hinshaw, Stephen, 3–4
 “Hippie crack”, 287
 Hippocampus
 and anxiety disorders, 165
 function of, 34
 and marijuana use, 278–279
 and methamphetamine use, 285
 and mood disorders, 125
 and neurocognitive disorders, 417
 and PTSD, 203
 and schizophrenia, 252
 Hippocrates, 9
 Hispanic Americans. *See also* Latinos
 alcohol use disorders for, 271
 eating disorders for, 326
 psychological disorders in, 46
 tobacco use by, 274
 Histrionic personality disorder, 441
 HiTOP model, 64
 HIV (human immunodeficiency virus), 183–184
Hoarders (television series), 196
 Hoarding disorder
 causes of, 192–193
 clinical description of, 186–188
 diagnosis of, 182
 prevalence and comorbidity of, 188
 psychological treatment of, 195–197
 in television shows, 22
 Holliday, Tess, 309
 Holmes, James, 462
 Holy Trinity Hospital (Salisbury, England), 10
 Homelessness, 4, 22, 188, 477
 Homosexuality, 336–340
 Hong Kong, 326
 Hopelessness, 146, 382, 385
 Hopelessness theory, 130
 Hospitalization, delirium and, 426
 Housing, 4
 HPA (hypothalamic-pituitary-adrenal) axis, 37, 117, 165, 252, 317, 381
 Hydrocodone, 281–282
 Hydromorphone, 282
 Hyperactive, term, 366
 Hyperactive-impulsive specifier, ADHD, 368
 Hypnosis, 15–16, 216, 217, 219–220, 234
 Hypochondriasis, term, 222
 Hypomania, 120, 122
 Hypothalamic-pituitary-adrenal axis. *See* HPA (hypothalamic-pituitary-adrenal) axis
 Hypothalamus, 34, 320
 Hypotheses, 85, 109
 Hysteria, 15, 232
- I**
 Iatrogenic, term, 219
 Ibn Sina, 9
 ICD (International Classification of Diseases), 58
 “Ice”, 284

- Id, 16
 Idaho, 463
 Ideal affect, 45
 Ideal body, 323–325
 Ideas of reference, 239, 440
 IED (intermittent explosive disorder), 373
 IEP (individualized education program), 392
 Illicit drug use. *See* Substance abuse
 Illicit substance dependence, 110
 Illness anxiety disorder, 65, 222
 causes of, 228
 clinical description of, 224
 diagnosis of, 222
 fear of impending, 230
 treatment of, 233–234
 Illusions, 440
 Imaginal exposure, 40, 205
 Immediate rewards, value of
 delayed vs., 291–292
 Immune system, 37–38, 393
 Impairment, paraphilic disorders
 and, 353
 Implicit memory, 41, 220
 Impulsivity, 358, 441, 444
 Inattentive specifier, ADHD, 368
 Incarceration, insanity plea and,
 459, 463
 Incentive-sensitization theory,
 290, 320
 Incest, 354–355
 Incidence, 91
 Independent variables, 93
 Index case (proband), 92
 India, 46, 59–60, 294, 325, 473
 Individualized education
 program (IEP), 392
 Individual psychology, 18
 Infants, 165, 397
 Infantile autism, 397
 Infectious diseases, 393
 Inferofrontal gyrus, 291
 Informal commitment, 471
 Information-processing biases,
 129
 Informed consent, 481–482
 Inhibition, behavioral, 165, 336
 Inpatient hospital treatment
 (alcohol use disorder), 297
 Insanity
 and capital punishment,
 469–470
 as legal concept/term, 458
 psychological disorder vs., 462
 Insanity defense, 459–465, 468,
 477
 Insanity Defense Reform Act,
 459–461
 Insertion, thought, 239
 Insomnia, 259, 412, 418
 Institute of Medicine, 279, 384
 Insulin coma therapy, 14
 Intellectual ability, 204
 Intellectual activities,
 engagement in, 418–419
 Intellectual disability, 389–394
 and autism spectrum disorder,
 398
 diagnosis and assessment of,
 469–470
 in DSM-5, 366
 etiology of, 392
 treatment of, 393–394
 Intelligence quotient (IQ), 28
 and autism spectrum disorder,
 399
 and conduct disorder, 376
 and intellectual disability,
 391–394
 and schizophrenia, 255–256
 Intelligence tests (IQ tests),
 74–75, 76
 Intermittent explosive disorder
 (IED), 373
 Intermittent reinforcement, 20
 Internal consistency reliability,
 54. *See also* Reliability
 Internal cues, attention to,
 169–170
 Internalizing behavior problems,
 367
 Internalizing disorders, 31. *See also*
 Anxiety disorders;
 Depression
 and ADHD, 369
 age of onset, 380
 and conduct disorder, 373–374
 conduct disorder treatments
 and, 379
 defined, 366
 diagnosis of, 64
 Internal validity, 94. *See also*
 Validity
 International Classification of
 Diseases (ICD), 58
 International List of Causes of
 Death, 58
 International Statistical
 Classification of Diseases,
 Injuries, and Causes of
 Death, 58
 International Test Commission,
 80
 Internet-based CBT, 176, 195,
 206–207, 234
 Internet-based cognitive therapy,
 136
 Internet-based ERP, 195
 Internet gaming disorder, 269
 Interoceptive conditioning, 172
 Interpersonal deficits, 440
 Interpersonal difficulties,
 depression and, 127–128
 Interpersonal factors, in the role
 of stress, 47–49
 Interpersonal fear disorder, 60
 Interpersonal therapy (IPT),
 47–49, 134, 137–138, 331
 Interpretation, 16
 Inter-rater reliability, 54, 66, 69.
 See also Reliability
 Interviews, 69–72
 assessing stress, 69–72
 clinical, 69–72, 76, 217, 432
 motivational interviewing, 298,
 302
 structured, 69
 unstructured, 69
 unstructured clinical, 432
 Intravenous drug use, 282
 Intrusion symptoms, PTSD, 200
 Inuit, 160–161
 Invalidation, 446
 In vivo exposure, 176
 Involuntary hospitalization, 475
 Involuntary nervous system. *See*
 Autonomic nervous system
 IPT. *See* Interpersonal therapy
 (IPT)
 IQ. *See* Intelligence quotient (IQ)
 IQ tests. *See* Intelligence tests
 Irresistible impulse, 460
 Israel, 102, 148
 Italy, 61, 102
- J**
Jackson v. Indiana, 465
 Jails, 12, 477–478
 Japan, 60–61, 102, 160, 186, 217,
 326
 Johnson, Virginia, 338
 Joint attention, 397, 401–402
 Jones, Michael, 460–461
 Judicial commitment, 471
 Jung, Carl, 18
- K**
 K2, 276
 Kanner, Leo, 397
 Kansas, 463
 Karlton, Lawrence, 478
 Kayak-angst, 160
 Kellogg's Corn Flakes, 336
 Kelly, Horace, 469
 Ketamine, 251, 287
Khyâl cap, 61
 Kinsey, Alfred, 340
 Knightley, Keira, 390
 Kohut, Heinz, 448
 Kraepelin, Emil, 58, 243
 Kuzmich, Heather, 397
 Kyle, Chris, 462
- L**
 La Bicêtre, 11
 Laborit, Henri, 258
 Lady Gaga, 326
 Lanugo, 312
 Late life, 409–431
 delirium in, 424–437
 dementia in, 413–424
 myths about, 406–407
 problems experienced in, 408
 psychological disorders in,
 409–413
 study of aging, research
 methods in, 408–409
 Latin America, 160, 415
 Latinos. *See also* Hispanic
 Americans
 anxiety disorders for, 160
 culturally competent treatment
 of, 102
 culturally relevant syndromes
 for, 61
 modified CBT, 103
 Laughing gas, 287
 Law of effect, 20
 LDL cholesterol, 421
 Lead, 371, 393
 Learning, 169, 443
 Learning disorders, 366,
 389–395
 Least restrictive alternative, 475
 Lebanon, 61, 102
 LEDS (Life Events and
 Difficulties Schedule), 71
- Legal issues, 457–483
 capital punishment, 469–470
 civil commitment, 470–479
 competency to stand trial,
 464–468
 criminal commitment,
 458–464
 deinstitutionalization,
 477–479
 ethical dilemmas, 480–483
 insanity defense, 459–463
 with paraphilic disorders, 362
 prediction of dangerousness,
 471–474
 preventive detention,
 471–474
 recovered memories of abuse,
 216
 rights of people with
 psychological disorders,
 475–479
 smoking bans, 300–301
 Legalization of marijuana, 279
 Leigh, Chyler, 5
 Levitra (vardenafil), 352
 Lewy bodies, dementia with, 421
 Life-course-persistent antisocial
 behavior, 374–376
 Life events
 and anxiety disorders, 166
 and depression, 130–131,
 136–137
 and depression in childhood/
 adolescence, 381–382
 and perceived lack of control,
 166
 Life Events and Difficulties
 Schedule (LEDS), 71, 76
 Lifestyle treatments, for
 dementia, 422–423
 Lifestyle variables, in Alzheimer's
 disease, 420
 Liking, wanting and, 290–291,
 320
 Limited prosocial emotions,
 conduct disorder, 374
 Lincoln, Abraham, 147
 Linehan, Marsha, 446, 454–455
 Liposuction, 323
 Lithium, 140–141
 Little Albert, 19, 168
 Littlefield, Chad, 462
 Lobotomy, 15
 Locus coeruleus, 165, 171, 203
 Loneliness, in late life, 407
 Longitudinal design, 90, 409
 Long-term memory, 413
 Loose associations (derailment),
 242
 Lortab, 281
 Lovaas, Ivar, 401
 Lovato, Demi, 5, 120
 Low positive emotion
 differentiation, 322
 Low sex drive, 343
 LSD (lysergic acid diethylamide),
 286
 Lunacy trials, 10
 Lunatics Tower, 11
 Lungs, effects of marijuana on,
 278
 Lysergic acid diethylamide (LSD),
 286

M

- MacArthur Violence Risk Assessment Study, 471
- Magnetic resonance imaging (MRI), 78, 400
- Maine, 275, 276
- Maintenance doses, 258
- Major depressive disorder (MDD). *See also* Depression
age of onset for, 117–118
antidepressants for, 138–141
and anxiety, 129
brain structures involved in, 125
and childhood sexual assault, 347
in children and adolescents, 380–381
cognitive theories for, 129–130
cognitive therapy for, 134–136
and dissociative identity disorder, 216
electroconvulsive therapy for, 139
epidemiology and consequences of, 139–140
and generalized anxiety disorder, 173
genetic influences in, 123
interpersonal therapy for, 134
in late life, 411
meta-analyses of, 110
neurobiological hypotheses about, 123
and posttraumatic stress disorder, 200
prevalence of, 91
and schizophrenia, 247
test–retest stability for, 433
- Maladaptive cognitions, 452
- Male hypoactive sexual desire disorder, 341
- Malingering, 222, 226
- Maltreatment, antisocial behavior and, 375–376
- Mammals, weight gain by nonhuman, 316
- Mandel, Howie, 183
- Mania. *See also* Bipolar disorders
in bipolar disorders, 119
brain structures involved in, 125
in children, 383–384
in DSM-II vs. DSM-5, 57
neurotransmitters involved in, 33
predictors of, 132
- Manic-depressive psychosis, 58
- MAOA gene, 376, 443
- MAOIs. *See* Monoamine oxidase inhibitors
- Marijuana, 276–279
in cross-national studies, 294
effects of, 277–279
expectancies and expectations about, 294
as gateway drug, 277
genetic factors and use of, 289
legalization of, 279
prevalence of use of, 276–277
and schizophrenia, 254
stimulant medication use and, 383–384
treatment for use of, 302
- U.S. population reporting use of, 268
young people's use of, 277
- Marijuana Anonymous, 297
- Marital distress, 66
- Marital therapy. *See* Couples therapy
- Mark of Shame, The* (Hinshaw), 4–5
- Mask of Sanity, The* (Cleckley), 441
- Massachusetts, 275, 276
- Mass hysteria, 232
- Masters, William H., 338
- Masturbation, 336, 339, 355
- Matrix treatment, 303
- Maturity, adolescence-limited antisocial behavior and, 374
- MBCT. *See* Mindfulness-based cognitive therapy (MBCT)
- MCI. *See* Mild cognitive impairment (MCI)
- MDD. *See* Major depressive disorder (MDD)
- MDMA (methylenedioxy-methamphetamine), 286–287
- Meanness, 442
- Means restriction, 148
- Media, 295, 324, 442
- Medial prefrontal cortex, 164
- Media reports, of suicide, 145
- Medication(s)
for ADHD, 372
for alcohol use disorder, 299
antipsychotic medication, 257–260
for anxiety, 178–179
for autism spectrum disorder, 402
for bipolar disorders, 140–141
black box warnings with, 383
for childhood and adolescent depression, 382–383
for childhood disorders, 383–384
and competency to stand trial, 467–468
and delirium, 426
for dementia, 422
for depressive disorders, 138–139
for drug use disorders, 303–305
for eating disorders, 329
for elderly people, 408, 412
forced, 467, 476–477
illicit prescription, 282–283
memory loss due to, 214
for mood disorders, 138
mood-stabilizing, 140–141
nicotine replacement, 301
for obsessive-compulsive related disorders, 194
and panic attacks, 172
for paraphilic disorders, 362
for personality disorders, 452
and polypharmacy, 408
for posttraumatic stress disorder, 205
prescription pain medication, 282
for rapists, 359
right to refuse, 476–477
- for schizophrenia, 257–260
and sexual dysfunction, 346, 351
and smoking cessation, 301
- Medication compliance, assisted outpatient treatment for, 473
- Medicines and Healthcare Products Regulatory Agency (MHRA), 383
- Meditation, mindfulness, 176
- Medroxyprogesterone (MPA, Depo-Provera), 361
- Megan's Law, 362
- Memantine (Namenda), 422
- Memory(-ies)
and bulimia nervosa, 323
and DID, 220
explicit, 220
implicit, 220
and norepinephrine, 214
procedural, 214
and PTSD, 203
recovered, 216
- Memory aids, 423
- Memory loss, 271
- Meningitis, 393
- Meningococcal meningitis, 393
- “Mental disease or defect”, 459–461
- Mental disorder, defined, 6
- Mental enfeeblement, 243
- Mental health courts, 478–479
- Mental health evaluations, 4
- Mental health professions, 23–24
- Mental hospitals, 12
- Mental illness. *See* Psychological disorders
- Mentalization therapy, 454
- Mentally Ill Offender Treatment and Crime Reduction Act, 478
- Menthol cigarettes, 274–275, 299
- Mercury, 384
- Mesmer, Franz Anton, 15–16
- Mesmerism, 15–16
- Meta-analysis, 109–110
- Metabolism, 272, 289
- Metabolites, 321
- Meta-cognitive skills, 423
- Methadone, 282, 302
- Methamphetamine (meth), 284–285, 303
- Methamphetamine Treatment Project, 303
- Methylenedioxy-methamphetamine (MDMA), 286–287
- Methylphenidate, 372
- Mexican Americans, 261
- Mexico, 60–61, 102, 261, 276
- MHRA (Medicines and Healthcare Products Regulatory Agency), 383
- Middle East, 61
- Migration, 254–255
- Mild cognitive impairment (MCI), 414–415
- Military service, 199
- Mind, structure of, 16–17
- Mind Freedom International, 5
- Mindfulness-based cognitive therapy (MBCT), 42, 136
- Mindfulness meditation, 176
- Minnesota Multiphasic Personality Inventory (MMPI, MMPI-2), 72–74, 80
- Miss Scott, 226
- MMPI. *See* Minnesota Multiphasic Personality Inventory
- MMR vaccine, 384
- M'Naghten, Daniel, 460
- M'Naghten rule, 460
- Mobile crisis units, 478
- Modeling, 20
- Model penal code, 460
- Moderation in drinking, 299
- Molecular genetics, 29–30, 248–250
- Molecular genetics research, 29, 123, 246, 248–250, 256–257
- Molly, 287
- Monahan, John, 473
- Moniz, Egas, 15
- Monoamine oxidase inhibitors (MAOIs), 138
- Monozygotic (MZ) twins, 93. *See also* Twin studies
- Montana, 463
- Mood
defined, 44
and delirium, 425
and PTSD, 199
- Mood disorders, 113–150
and binge eating disorder, 317
bipolar, 119–122, 137–138, 140–141
clinical descriptions of, 114–118, 119–120
defined, 113
depression, 114–118, 128–131, 134–137
epidemiology and consequences of, 116–118, 121
influences on, 122–133
international prevalence of, 61
medications for, 138–141
and personality disorders, 431
prevalence of, 91
and somatic symptom and related disorders, 223
and suicide, 142–149
treatment of, 134–142
- Mood-stabilizing medications, 140–141
- Moral awareness, 376
- Moral treatment, 11–12
- Morphine, 282
- Motivation, enhancing, 361
- Motivational interventions, 298–299
- Motivational interviewing, 302, 303
- Motivation and pleasure domain, 241
- Motor disorders, 366, 390
- Mowrer's two-factor model, 162
- MPA (medroxyprogesterone), 361
- MRI. *See* Magnetic resonance imaging (MRI)
- MST. *See* Multisystemic treatment (MST)
- Multiaxial classification system, 58

- Multimodal Treatment of Children with ADHD (MTA) study, 372–373, 383
- Multiracial individuals, alcohol use disorders among, 271
- Multisystemic treatment (MST), 378–380
- Munchausen syndrome by proxy, 226
- MZ (monozygotic) twins, 93. *See also* twin studies
- N**
- Naloxone, 305
- Naltrexone, 299, 305
- Namenda (memantine), 422
- NAPLS (North American Prodrome Longitudinal Study), 256
- Narcissism, adaptive, 448
- Narcissistic personality disorder, 446–451
- etiology of, 448
- heritability of, 437
- inter-rater reliability for, 433
- key features of, 431
- maladaptive cognitions with, 452
- prevalence of, 432
- risk factors for, 437
- Narcissus, 448
- Narcotics Anonymous, 297
- Nathaniel, 242
- National Alliance on Mental illness, 5
- National Association of Social Workers, 147
- National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 481
- National Comorbidity Survey-Replication (NCS-R) study, 91, 153, 410–411
- National Institute of Aging, 414
- National Institute of Mental Health (NIMH), 64, 100, 109, 481
- National Institute on Alcohol Abuse and Alcoholism (NIAAA), 273
- National Institutes of Health (NIH), 107, 275
- National Sheriffs' Association, 12
- National Survey on Drug Use and Health, 5
- Native Americans
- alcohol use disorders among, 271
- cultural bias in assessment with, 82
- cultural competence with, 103
- cultural concepts of distress, 61
- tobacco use by, 274
- Navane (thiothixene), 259
- NAVIGATE treatment, 264
- NCS-R study. *See* National Comorbidity Survey-Replication (NCS-R) study
- Neal, Shannon, 142
- Neal, Steven, 142
- Negative affectivity, 435
- Negative beliefs, 166, 169, 199, 348
- Negative emotions, 135, 291–294, 322
- Negative emotionality, 294
- Negative mood, eating and, 321–322
- Negative reinforcement, 20
- Negative self-perceptions, of older adults, 408
- Negative symptoms, 240–241
- Negative thoughts, challenging, 136
- Negative triad, 129
- NEO Personality Inventory (NEO-PI), 74
- Nervous system
- autonomic, 36, 376
- parasympathetic, 36
- sympathetic, 36
- Netherlands, 61, 102, 325, 448
- Neurobiological assessment, 77–80
- brain imaging, 78–79
- brain stimulation, 79
- Neurobiological influences
- in anxiety disorders, 164–165
- in autism spectrum disorder, 400–401
- in borderline personality disorder, 446
- in conduct disorder, 376
- in eating disorders, 320–321
- in mood disorders, 123
- in panic disorder, 171
- in paraphilic disorders, 358
- in posttraumatic stress disorder, 203
- in somatic symptom disorders, 231–232
- in substance use disorders, 289–292
- in suicide, 145
- Neuroendocrine system, 37
- Neurofibrillary tangles, 416–417
- Neuroleptics. *See* Antipsychotic drugs (antipsychotics)
- Neurons, 33–34, 252, 417–420
- Neuropsychiatric symptoms, with dementia, 413
- Neuropsychological influences (conduct disorder), 376
- Neuropsychological tests, 75, 252
- Neuroscience influences (psychopathology), 33–39
- autonomic nervous system, 36
- evaluating, 38–39
- functional neurological symptom disorder, 231–232
- immune system in, 37–38
- neuroendocrine system in, 37
- and neurons/neurotransmitters, 33–34
- and structure/function of brain, 34–35
- treatment approaches, 38
- Neuroticism, 128–129, 162, 165, 229
- Neurotransmitters, 33–34
- in anxiety disorders, 33, 164–165
- in eating disorders, 319–321
- in schizophrenia, 250–252
- Neutral predictable unpredictable (NPU) threat task, 163
- Nevada, 276
- New Zealand, 102, 255, 278, 375, 472
- NGRI. *See* Not guilty by reason of insanity
- NIAAA (National Institute on Alcohol Abuse and Alcoholism), 273
- Nicotine, 274. *See also* Cigarette smoking
- and ADHD, 371
- and alcohol use, 468–469
- metabolism of, 289
- and negative emotion, 293
- tension/stress and consumption of, 293
- Nicotine patches, 301
- Nicotine replacement therapy (NRT), 301
- Nigeria, 59, 61, 102
- NIH (National Institutes of Health), 275
- NIMH. *See* National Institute of Mental Health
- Nitrous oxide, 287
- NMDA (N-methyl-D-aspartate acid), 63, 251
- N-methyl-D-aspartate (NMDA) receptor, 138
- Noncompliance, 366, 368
- Nonconsenting others, paraphilic disorders and, 353, 355, 356, 358
- Nonepileptic seizure disorder, 225
- Nonshared (unique) environment, 27
- Nonsuicidal self-injury (NSSI), 142–143, 199
- Norepinephrine, 33
- and anxiety disorders, 165, 171
- and memory, 214
- Norms, 336
- North American Prodrome Longitudinal Study (NAPLS), 256
- North Carolina, 270, 369
- Northern Ireland, 201
- Norway, 294
- Not guilty by reason of insanity (NGRI), 460–462
- No-treatment control group, 101
- Not So Subtle Art of Being a Fat Girl, The* (Holliday), 309
- NPU (neutral predictable unpredictable) threat task, 163
- NSSI. *See* Nonsuicidal self-injury (NSSI)
- Nucleus accumbens, 283, 290, 292, 371
- Null hypothesis, 89
- Nuremberg Code, 481
- Nuremberg Trials, 481
- Nuthkavihak*, 45
- O**
- Obese, term, 314
- Obesity, 314–318, 323–325
- Objectification theory, 325
- Obsessions, 183–185
- Obsessive-compulsive disorder (OCD)
- and anorexia nervosa, 312
- anxiety disorders and, 153, 159
- behavioral treatment for, 38
- and body dysmorphic disorder, 185–186
- causes of, 190–192
- in children, 382, 386–387
- classification of, 59
- clinical description of, 183–185
- and deep brain stimulation, 197
- diagnosis of, 182
- empirically supported treatments for, 99
- obsessive-compulsive personality disorder vs., 450–451
- prevalence of and comorbidity with, 188
- psychological treatment of, 194–197
- in SCID, 70
- television shows on, 22
- Obsessive-compulsive personality disorder, 450–451
- heritability of, 437
- inter-rater reliability for, 433
- key features of, 182, 431
- maladaptive cognitions with, 452
- prevalence of, 452
- test-retest stability for, 433
- Obsessive-compulsive-related disorders, 181–209
- causes of, 189–193
- clinical descriptions of, 182–189
- comorbidity with, 188
- diagnoses of, 182
- epidemiology of, 182
- prevalence of, 188
- treatment of, 193–197
- Occipital lobe, 35
- OCD. *See* Obsessive-compulsive disorder (OCD)
- O'Connor v. Donaldson*, 476
- ODD. *See* Oppositional defiant disorder (ODD)
- Odd/eccentric cluster (personality disorders), 431, 439–440
- Odyssey House, 302
- Olanzapine (Zyprexa), 38, 138, 141, 259, 260, 435
- Older adults. *See* Age and aging; Late life
- Olsen, Mary-Kate, 331
- Online social interactions, 369
- Operant conditioning, 20, 39–40, 162, 169, 202, 234, 372, 393, 401
- Operation Desert Storm, 202
- Opioid antagonists, 303
- Opioids, 280–283
- effects of, 282–283
- prevalence of use, 282
- substitutes, 303
- withdrawal from, 302
- Opium, 281
- Oppositional defiant disorder (ODD), 65, 373–374, 383
- Orbitofrontal cortex, 189
- Oregon, 275, 277

- Organizational abilities, 192
 Orgasmic disorders, 341, 343–344, 351
 Orgasm phase (sexual response cycle), 340
 Other hallucinogen use disorder, 286
 Outcome research. *See* Treatment outcome research
 Outpatient treatment, assisted, 473
 Overweight, 310
 Oxycodone, 281
 OxyContin, 281–282
 Oxymorphone, 282
- P**
- Pain, somatic symptom disorders and, 222, 229, 234
 Pain medications, misuse of, 268
 Panetti, Scott, 469
 Panic, 99, 410
 Panic attacks
 analogue studies of, 105
 cognitive factors in, 172–173
 defined, 157
 depersonalization in, 213
 Panic disorder, 62, 153
 and anorexia nervosa, 312
 clinical description of, 153, 157
 emotions with, 45
 influences on, 171–173
 prevalence of, 91
 psychological treatment of, 177–178
 Paracelsus, 10
 Paranoid personality disorder, 429, 439
 in Alternative DSM-5 model, 434–436
 comorbidities for, 434
 inter-rater reliability for, 433
 key features of, 431
 prevalence of, 432
 Paraphilic disorders, 352–363
 causes of, 357–360
 clinical descriptions, 352–357
 defined, 352
 in DSM-5, 353
 treatment for, 360–363
 Parental affection, 437
 Parental monitoring, 40, 377
 Parent–child relationships, 18, 379
 Parent management training (PMT), 377–378
 Parents and parenting
 and ADHD, 371
 and antisocial personality disorder, 464
 and autism spectrum disorder, 443
 and borderline personality disorder, 445
 and childhood anxiety, 387
 and conduct disorder, 378
 and eating disorders, 327–328
 and narcissistic personality disorder, 448
 and personality disorders, 437–438
 Parent training, 372–373
 Parkinson's disease, 250, 258
Pate v. Robinson, 465
 Pathological gambling disorder, 269
 Patient Outcomes Research Team (PORT), 261
 Patients Like Me, 5
 Patterson, Gerald, 377
 Pavlov, Ivan P., 19
 PCP (phencyclidine), 252, 286–288
 PDE-5 (phosphodiesterase type 5) inhibitors, 352
 Pediatric OCD Treatment Study (POTS), 388
 Pedophilic disorder, 354–355
 effects of, 347
 prevalence of, 354
 Peel, Sir Robert, 460
 Peer influences (conduct disorder), 377
 Peer relationships, social anxiety and, 386
 Penile plethysmograph
 defined, 338
 in diagnosis of pedophilic disorder, 354–355
 measuring arousal with, 340
 Pepsi, 316
 Perceived control, 160
 Perception, disturbances of, 424–445
 Percodan, 281
 Perfectionism, 311, 327–328
 Perinatal factors (in ADHD), 371
 Perphenazine, 259
 Persistent depressive disorder, 114–118
 Personal contact, 4
 Personal distress, 7
 Personality
 in analytical psychology, 18
 and anxiety disorders, 165
 and childhood experiences, 18
 and eating disorders, 327–328
 Personality disorders, 429–456
 and anorexia nervosa, 312
 anxious/fearful cluster of, 429
 and bulimia nervosa, 313
 defined, 429
 and dissociative identity disorder, 216
 in DSM-5, 431–434
 odd/eccentric cluster of, 431–434, 439–440
 and posttraumatic stress disorder, 200
 risk factors for, 436–438
 and somatic symptom and related disorders, 223
 stability, 433
 treatment of, 452–454
 Personality factors (substance use disorders), 294
 Personality inventories, 72–74
 Personality tests, 72–74, 76
 personality inventories, 72–74
 Personality trait domains, 435–436
 Personality trait facets, 435–436
 Personal responsibility, obesity and, 317
 PET (positron emission tomography) scan, 78, 418
 p (psychopathology) factor, 65
 PGC (Psychiatric Genomics Consortium), 249
 p-hacking, 108
 Ph.D. degree, 23
 Phelps, Michael, 370
 Phencyclidine, 252, 286–288
 Phenothiazines, 258
 Phenotype, 28
 Phenylketonuria (PKU), 392
 Phobia(s). *See also Specific phobias*
 and classical conditioning, 19–20
 distress/disability from, 7
 empirically supported treatments for, 99
 food, 95
 psychological treatment of, 176
 Phoenix House, 302
 Phosphodiesterase type 5 (PDE-5) inhibitors, 352
 Physical conditions, psychological disorders in late life and, 408
 Physical consequences
 of anorexia nervosa, 312
 of binge eating disorder, 318
 of bulimia nervosa, 314
 of marijuana use, 278–279
 Physical effects, of opioids, 282–283
 Physicians
 psychological services referrals from, 232
 psychological treatment for cigarette smoking by, 300
 Physician's certificate, 471
 Physiological arousal, sexual dysfunction and, 346–348
 Physiological component of emotion, 44
 Physiological measure of emotion, 44
 Pica, 309
 Pick's disease, 421
 Pinel, Philippe, 11
 Pituitary gland, 37
 PKU (phenylketonuria), 392–393
 Placebo, 101
 Placebo effect, 101
 Plaques, 416–418
 Pleasure, anhedonia and, 240–241
 PMT (parent management training), 377–378
 Poddar, Prosenjit, 473–474
 Point systems, for children with ADHD, 373
 Police, mobile crisis units and, 478
 Polygenic risk score, 30
 Polygenic, term, 27
 Polymorphism, 29
 Polypharmacy, 408
 Pornography, 339
 PORT (Patient Outcome Research Team), 261
 Portion size, 316
 Positive emotion, drug use and, 293
 Positive reinforcement, 20
 Positive symptoms, 239–240
 Positron emission tomography. *See* PET (positron emission tomography) scan
 Postsynaptic neurons, 33
 Posttraumatic model (of DID), 218–219
 Posttraumatic stress disorder (PTSD), 198–207
 and childhood sexual assault, 347
 in children and adolescents, 38, 380–382
 clinical description of, 198–201
 co-diagnoses with, 64, 65
 and dissociative identity disorder, 216
 empirically supported treatments for, 99
 epidemiology of, 198–201
 etiology of, 201–204
 and insanity defense, 462
 treatment of, 205–207
 Potential victims, protection for, 474
 Potential victims yet unknown, 474
 Poverty, 45, 254–255, 281, 376, 443
 Prediction of dangerousness, 472–473
 Predictive power, of research, 84
 Prefrontal cortex, 34
 and borderline personality disorder, 446
 and conduct disorder, 376
 development of, 257
 in mood disorders, 124
 and PTSD, 203
 and schizophrenia, 251–252
 and valuing of rewards, 292
 Prefrontal lobotomy, 15
 Pregnancy
 ADHD and smoking during, 371
 alcohol consumption during, 273
 cocaine use during, 285–286
 intellectual disability and infections during, 393
 schizophrenia and infections during, 253
 Premature ejaculation, 341, 343, 351
 Premenstrual dysphoric disorder, 114
 Premotor areas, brain, 291
 Prenatal factors, in ADHD, 371
 Prepared learning, 169
 Prescription medication, illicit, 280–282. *See also* Medication(s)
 Presidents, adaptive narcissism of, 448
 Prevalence, 91
 Preventive detention, 471–472
 Preventive interventions (eating disorders), 332
 Primary care interventions (somatic symptom disorders), 233
 Principle of reinforcement, 20
 Prison inmates, 441
 Prisons, 12, 477–478
 Privileged communication, 473, 482
 Pro-ana websites, 324

- Proband, 92
 - Problem-solving deficits, suicide and, 146
 - Procedural memory, 214
 - Prodrome, 245
 - Pro-eating disorder websites, 325
 - Pro-inflammatory cytokines, 38, 125–126
 - Project EX, 300
 - Projection, 17
 - Projective test, 72
 - Prolixin (fluphenazine), 259
 - Prolonged trauma, PTSD and, 199
 - Pro-mia websites, 324
 - Pronoun reversal, 397
 - Proof, standards of, 461
 - Property, protection of, 474
 - Prospective studies (schizophrenia), 255–256
 - Prozac. *See* Fluoxetine
 - Pruning, 35, 253–254, 400
 - Psilocybin, 286
 - Psychiatric Genomics Consortium (PGC), 249
 - Psychiatric hospitals, need for, 477–478
 - Psychiatric nurses, 24
 - Psychiatrists, 24
 - Psychoactive medications, 22–23, 383
 - Psychoanalysis (psychoanalytic therapy), 16–19
 - Psychodynamic theories, 18, 214, 231, 448, 452–453
 - Psychodynamic therapies/treatment
 - for anorexia nervosa, 329–330
 - for dissociative identity disorder, 221
 - for personality disorders, 452–453
 - Psychoeducation, 5
 - Psychoeducational approaches, 47
 - for bipolar disorder, 137
 - for childhood anxiety, 388–389
 - for dissociative identity disorder, 221
 - for eating disorder prevention, 332
 - for schizophrenia, 263
 - for sexual dysfunction, 350
 - Psychological approach to psychological disorders, 15–21
 - analytical psychology, 18
 - behaviorism, 18–21
 - cathartic method, 16
 - cognition in, 20–21
 - defense mechanisms, 17
 - individual psychology, 18
 - mesmerism and hypnosis, 15–16
 - psychoanalysis, 16–19
 - structure of the mind, 16–17
 - Psychological assessment, 68–77
 - behavior, direct observation of, 75
 - clinical interviews, 69–72
 - cognitive tests, 74–75
 - experience sampling, 76
 - intelligence tests, 74–75
 - methods, 76
 - neuropsychological tests, 74–75
 - personality tests, 72–74
 - self-report questionnaires, 76
 - of stress, 69–72
 - Psychological disorders. *See also specific disorders*
 - advancements in, 22
 - civil rights of people with, 475–479
 - and crime, 459
 - defined, 2, 6
 - and disability, 7
 - and dysfunction, 7
 - emotion and, 44–45
 - history of, 8–13
 - and homelessness, 475
 - insanity vs., 462
 - international prevalence of, 61
 - interpersonal factors in, 47–49
 - in late life, 410–411
 - living conditions of people with, 22–23
 - marital distress rates and missed workdays for people with, 66
 - and personal distress, 7
 - stigma associated with, 2–6
 - and suicide, 145
 - violence linked to, 471–472
 - Psychological distress, 152
 - Psychological effects of marijuana, 278
 - of opioids, 282–283
 - Psychological influences
 - in ADHD, 372–373
 - in conduct disorder, 376–377
 - in mood disorders, 128–131
 - in paraphilic disorders, 358, 360
 - in schizophrenia, 254–256
 - in sexual functioning, 345–348
 - in substance use disorders, 292–294
 - and suicide, 146
 - Psychological factors affecting other medical conditions, 224
 - Psychological risk, psychopathy and, 443–444
 - Psychological stress. *See* Stress
 - Psychological treatments
 - of ADHD, 372–373
 - of anorexia nervosa, 329–330
 - for anxiety disorders, 175–178
 - of binge eating disorder, 331–332
 - of bipolar disorder, 137–138
 - of bulimia nervosa, 330–331
 - for cigarette smoking, 300–301
 - culture and ethnicity in, 103
 - of dementia, 422
 - of depression, 134–137
 - of drug use disorders, 302–305
 - of obsessive-compulsive-related disorders, 194–197
 - of schizophrenia, 261–265
 - of trauma-related disorders, 205–207
 - Psychology
 - analytical, 18
 - individual, 18
 - self-, 448
 - Psychomotor agitation, 115
 - Psychomotor retardation, 115
 - Psychopathology, 2
 - advancements in, 22
 - estimating prevalence of, 412
 - research designs in, 85–97
 - sociocultural factors in, 45–46
 - Psychopathology (p) factor, 65
 - Psychopathy, 441–444
 - clinical descriptions of, 441–442
 - etiology of, 443–444
 - media images of, 442
 - Psychopathy Checklist–Revised (PCL-R), 442
 - Psychosocial treatments (schizophrenia), 261–265
 - Psychotherapeutics, 277
 - Psychotherapy, 17. *See also*
 - Psychological treatments; *specific disorders*
 - for dementia, 422–443
 - for dissociative identity disorder, 221
 - for personality disorders, 452
 - Psychotic disorders. *See* Schizophrenia
 - Psychoticism, 435
 - Psy.D. degree, 24
 - PTSD. *See* Posttraumatic stress disorder (PTSD)
 - Publication bias, 107
 - Public figures, diagnosing, 480
 - Public, protecting, 362–363
 - Puerto Rico, 7, 201
 - Purging, 313
 - Pussin, Jean-Baptiste, 11
- Q**
- Questionable research practices, 108
 - Quetiapine (Seroquel), 259
- R**
- RAISE (Recovery After an Initial Schizophrenia Episode) Early Treatment Program, 264
 - Random assignment, 86, 93–94, 98
 - Randomized controlled trials (RCTs), 98, 104, 360
 - Random variation, 89
 - Rape, 359
 - Rationalization, 17
 - Rayner, Rosalie, 19
 - RCTs. *See* Randomized controlled trials (RCTs)
 - RDoC (research domain criteria), 64
 - Reactivity, 199
 - Reagan, Ronald, 416, 460–461
 - Rebirthing, 100
 - Recessive-gene diseases, 392–393
 - Recovered memories, 216
 - Recovered-memory techniques, 100
 - Recovery After an Initial Schizophrenia Episode (RAISE) Early Treatment Program, 264
 - Referrals, from physicians, 232
 - Reinforcement, 20, 219
 - Rejection, by peers, 377
 - Relapse, by people with schizophrenia, 261–263
 - Relapse prevention, 297, 361
 - Relationship distress and problems
 - empirically supported treatments for, 99
 - and personality disorders, 429
 - and sexual dysfunctions, 343, 347, 350
 - Relaxation, 172
 - Relaxation training, 178
 - Reliability, 54–55, 66
 - Repetitive acts, 398
 - Replication, 107–109
 - Reporting bias, 412
 - Representative samples, 86, 91
 - Repression, 17, 216, 221
 - Research domain criteria (RDoC), 64
 - Research methods, 84–112
 - analogues in, 105–107
 - case studies, 91–93
 - correlational method, 86–93
 - experiments, 93–97
 - for integrating study findings, 107–110
 - in psychopathology, 85–97
 - in study of aging, 408–409
 - theory and hypotheses, 84–85
 - treatment outcome research, 98–105
 - Research, restraints on, 480–481
 - Residency, 24
 - Residential treatments, 296, 305, 393
 - Resistance, 71
 - Resolution phase (sexual response), 340
 - Reston, Ana Carolina, 312
 - Restraints on research, 480–481
 - Reuptake, 33
 - Reversal (ABAB) design, 96
 - Reward sensitivity, 132
 - Rewards, immediate vs. delayed, 291–292
 - Reward system, 125, 132, 316
 - Rey Complex Figure Test, 75
 - Ricci, Christina, 326
 - Right to refuse treatment, 476–477
 - Right to treatment, 475–476
 - Rinaldi, Gina, 210
 - Risk calculator (schizophrenia), 256
 - Risk factors
 - for anxiety disorders, 161–168
 - in eating disorder prevention, 332
 - for personality disorders, 436–438
 - Risperdal (risperidone), 259, 402, 453
 - Risperidone (Risperdal), 259, 402, 453
 - Ritalin, 372
 - Rituals and ritualistic acts, 398
 - Rivastigmine (Exelon), 422
 - RNA, 29
 - Role disputes, 48
 - Role-playing, of DID symptoms, 220
 - Role transitions, 48
 - Rorschach Inkblot Test, 73
 - Routh, Eddie Ray, 462

- Routines, teaching children, 394
 rTMS (transcranial magnetic stimulation), 140
 Rubens, Peter Paul, 323
 Rumination, 130
 Rumination disorders, 309
 Rumination theory, 130–131
 Rush, Benjamin, 11
 Russia, 19, 301
- S**
 Sacks, Oliver, 399
 Safety behaviors, 166, 169, 177, 230, 233
 Saks, Elyn, 468
 Sambians, 336
 SAMHSA (Substance Abuse and Mental Health Services Administration), 267, 270, 277
 Samples, 101–102
 Satiation, 361
 SB5 (Stanford–Binet, 5th edition), 74
 Scared Straight, 100
 Schema, 40–41
 Schizoaffective disorder, 243
 Schizoid personality disorder, 439
 in Alternative DSM-5 model, 434
 inter-rater reliability for, 433
 key features of, 431
 prevalence of, 432
 Schizophrenia, 237–266
 and brain, 252–253
 causes of, 245–257
 clinical descriptions of, 238–245
 cultural bias in diagnosis of, 81–82
 defined, 238
 developmental factors in, 255–256
 disorganized symptoms of, 241–243
 electroconvulsive therapy for, 15–16
 emotional expression with, 45
 empirically supported treatments for, 99
 environmental factors and, 253–254
 ethnicity and prevalence of, 46
 family therapy in treatment for, 47
 functional connectivity with, 35
 gender differences in, 46
 genetic factors in, 246–250
 heritability of, 14–15
 history of concept of, 243
 and informed consent, 481–482
 medication-based treatment of, 257–265
 misdiagnosis of, 63
 negative symptoms of, 240–241
 and neurotransmitters, 250–252
 in older adults, 410
 positive symptoms of, 239–240
 psychoactive medications for, 22
 psychological influences on, 254–256
 psychological treatments of, 261–265
 researching, 92
 and schizotypal personality disorder, 440
 sociocultural factors in, 45–46
 treatment of, 257–265
 Schizophrenia spectrum disorders, 244, 471
 Schizophrenia Working Group, 123, 249
 Schizophreniform disorder, 243
 Schizophrenogenic mother, 253
 Schizotypal personality disorder, 439–440
 comorbidities for, 434
 heritability of, 437
 inter-rater reliability for, 433
 key features of, 431
 prevalence of, 432
 test–retest stability for, 433
 School interventions (specific learning disorders), 393–394
 Schumann, Robert, 122
 SCID (Structured Clinical interview), 69
 Science, 84–85
 Second-degree relatives, 92
 Second-generation antipsychotic drugs, 258–260
 Secondhand smoke, 275
 Selective mortality, 409, 412
 Selective mutism, 386
 Selective prevention programs, 385
 Selective serotonin reuptake inhibitors (SSRIs), 138
 and mood disorders, 138–139
 and obsessive-compulsive disorder, 194
 and PTSD, 205
 and sexual function, 346
 for treatment of anxiety and depression, 64
 for treatment of anxiety disorders, 179
 for treatment of paraphilic disorders, 362
 Self-blame, 348
 Self-critical beliefs, 143
 Self-esteem, 322–323, 448
 Self-evaluation, social anxiety disorder and, 169–170
 Self-help groups, 297
 Self-help residential programs, 302
 Self-image, 323–324
 Self-monitoring, 76
 Self-objectification, 325
 Self-overestimation of social performance, by children with ADHD, 368
 Self-perceptions, negative, 408
 Self-psychology, 448
 Self, sense of, 445
 Self-stimulatory activities, 398
 Selye, Hans, 71
 Sensate focus, 350–351
 Separation anxiety disorder, 380, 386, 388
 Sequenced Treatment Alternatives to Relieve Depression (STAR-D) trial, 139
 Seroquel (quetiapine), 259
 Serotonin 1A agonist, 138
 Serotonin, 33
 and alcohol, 271
 and anxiety disorders, 165
 and eating disorders, 320–321
 and Ecstasy, 287–288
 and hallucinogens, 286–287
 and methamphetamine use, 285
 and schizophrenia, 251
 and suicide, 145
 Serotonin-norepinephrine reuptake inhibitors (SNRIs), 138
 and mood disorders, 138–139
 for treatment of anxiety disorders, 179
 Serotonin transporter gene, 381–382
 Sertraline (Zoloft), 388
 SES (socioeconomic status), 28
 Sex drive, low, 343
 Sex offenders, 361–363
 Sex-reassignment surgery, 338
 Sexual abuse. *See* Childhood sexual abuse (CSA)
 Sexual anatomy, 339
 Sexual desire disorders, 341
 Sexual disorders, 330–364
 paraphilic disorders, 352–363
 sexual dysfunctions, 340–352
 and sexual norms, 336–340
 Sexual dysfunctions, 340–352
 causes of, 345–348
 and childhood sexual assault, 365
 clinical descriptions of, 340–346
 DSM-5 criteria for, 341
 empirically supported treatments for, 99
 orgasmic disorders, 343–344
 prevalence of, 341
 sexual interest, desire, and arousal disorders, 342–343
 sexual pain disorders, 344–345
 treatments of, 349–352
 Sexual impulse control strategies, 361
 Sexual interest, 342–343
 Sexual interest, desire, and arousal disorders, 340–344
 Sexuality, 336, 338–340
 Sexual masochism disorder, 353–354, 356–357
 Sexual norms, 336–340
 Sexual pain disorders, 344–345, 351
 Sexual performance, cognitions about, 346
 Sexual sadism disorder, 353–354, 356–357
 Shame, body, 325
 Shared environment, 27
Shenjing shuairuo, 60
 Sickness behavior, 125
 Sidibe, Gabourey, 325
 Significance
 clinical, 88–90
 statistical, 88–90, 109, 289
 Sildenafil (Viagra), 352
 Simple phobia, 99
 Sinatra, Frank, 122
 Single-case experimental design, 86, 94–96
 Single nucleotide polymorphisms (SNPs), 29–30, 123, 249, 289, 400
 Skin conductance tests, 376, 443
 Skinner, B. F., 20
 Sleep
 and aging, 408
 circadian rhythms and, 126–127
 disturbances in, 212, 413, 425
 and mania, 132
 Smoke-free environments, 275
 Smoking. *See* Cigarette smoking
 Smoking-cessation programs, 291, 301
 SNPs. *See* Single nucleotide polymorphisms (SNPs)
 SNRIs (serotonin-norepinephrine reuptake inhibitors), 141
 Social anxiety, 386–388, 398
 Social anxiety disorder(s), 62. *See also* Social phobia
 and avoidant personality disorder, 449
 in children and adolescents, 380, 387–388
 clinical description of, 156
 influences on, 169–171
 prevalence of, 154
 psychological treatment of, 177
 Social-cognitive perspective (aggressive behavior), 376
 Social (pragmatic) communication disorder, 390
 Social cues, attention to, 170
 Social deficits, 48
 Social disturbances (with ASD), 396–397
 Social influences (antisocial personality disorder), 443
 on anxiety disorders, 160–161
 on bipolar disorders, 132
 on body dysmorphic disorder, 185–186
 on conduct disorder, 375–376
 in depression, 117, 127–128
 functional neurological symptom disorder, 231–232
 in quitting smoking, 300
 in sexual functioning, 347
 in substance use, 294–295
 and suicide, 145
 Social information processing, antisocial behavior and, 377
 Social networks, 295
 expansion of, 263
 Social performance, self-overestimation of, 368
 Social phobia, 99. *See also* Social anxiety disorder(s)
 Social relationships, frontotemporal dementia and, 419–420
 Social selectivity, 407
 Social skills, of children with ADHD, 368
 Social skills training, 99, 261, 264
 Social support, 128, 204
 Social workers, 24
 Sociocognitive model (of DID), 219–220

- Sociocultural influences
 - in eating disorders, 323–324
 - in psychopathology, 45–46
 - in schizophrenia, 254–255
 - in substance use disorders, 294–295
 - Socioeconomic status (SES), 28
 - Sodium pentothal, 219
 - Soloist, The* (Lopez), 242
 - Somatic symptom and related disorders, 210–236
 - causes of, 228
 - clinical descriptions of, 222–228
 - diagnoses of, 222
 - in late life, 407
 - mechanisms of, 229–230
 - treatment of, 233–234
 - Somatic symptom disorder, 110, 222
 - clinical description of, 223–224
 - diagnosis of, 222
 - and dissociative identity disorder, 216
 - with pain, 234
 - treatment of, 233–234
 - Somatic symptoms, 177, 228–229
 - Somatoform disorder, 223
 - Somatosensory cortex, 228
 - South Africa, 102
 - South Asia, 160
 - SP (symbolic play), 402
 - Spain, 61, 102, 301
 - Specialness, 448
 - Specific learning disorder, 389–394
 - Specific phobias, 163
 - in adolescents, 380–381
 - and anorexia nervosa, 312
 - and autism spectrum disorder, 398
 - clinical description of, 154–155
 - influences on, 168–169
 - prevalence of, 91
 - psychological treatment of, 176
 - types of, 155
 - SPECT scan, 78
 - Speech, 241–242
 - Speech sound disorder, 390
 - Spellbound* (film), 214
 - Spice, 276
 - Squeeze technique, 351
 - SSRIs. *See* Selective serotonin reuptake inhibitors (SSRIs)
 - Stable attributions, 130
 - Standardization, 72
 - Stanford–Binet, 5th edition (SB5), 74
 - Starbucks, 284
 - STAR-D (Sequenced Treatment Alternatives to Relieve Depression) trial, 139
 - Star Trek* (television series), 399
 - Statistical significance, 88–90, 109, 289
 - Stelazine (trifluoperazine), 259
 - Stereotypes, 74–75, 103, 321, 324
 - Stereotype threat, 74–75
 - Stereotypic behavior, 398
 - Stereotypic movement disorder, 390
 - Sterilization (mentally ill), 14
 - Stigma, 2–6
 - and diagnosis, 67
 - of drug and alcohol use disorders, 369
 - of eating disorders, 309
 - fighting against, 4–5
 - of obesity, 317
 - and psychological disorders on television, 22
 - of somatic symptom and related disorders, 223
 - Stimulants (stimulant medications), 283–286
 - for ADHD, 38, 372
 - amphetamines, 283–285
 - caffeine, 284
 - for childhood disorders, 383
 - cocaine, 285–286
 - Stone, Emma, 157
 - STOPP/START system, 408
 - Strattera, 372
 - Stress, 69–72
 - and alcohol/nicotine consumption, 292
 - and bulimia nervosa/binge eating disorder, 322
 - and depersonalization/derealization disorder, 212–213
 - and depression, 117
 - and dissociation, 214
 - and dissociative amnesia, 215
 - and eating, 317
 - history of, 71
 - hormones related to. *See* Cortisol
 - and immune system functioning, 37–38
 - and schizophrenia, 254
 - Striatum, 123–125
 - Strong, 365, 5
 - Structural connectivity, 35
 - Structured Clinical Interview (SCID), 69, 76
 - Structured interviews, 69
 - Studies in Hysteria* (Breuer & Freud), 16
 - Stuttering, 390
 - Styron, William, 114
 - Subjective feeling, 44
 - Subjective Units of Distress Scale (SUDS), 95
 - Sublimation, 18
 - Suboxone (buprenorphine), 282, 305
 - Substance abuse. *See also* Alcohol abuse; Drug abuse
 - and ADHD, 369
 - and antisocial personality disorder, 443
 - and childhood sexual assault, 347
 - and conduct disorder, 373–374
 - in late life, 412
 - and memory loss, 214
 - and posttraumatic stress disorder, 200
 - and violence by mentally ill persons, 471
 - Substance Abuse and Mental Health Services Administration (SAMHSA), 267, 270, 412
 - Substance dependence, 110
 - Substance use
 - conduct disorder treatments and, 379
 - drug use and ADHD medications, 383
 - prevalence of drug use, 267–268
 - and schizophrenia, 238
 - Substance use disorders, 267–307
 - alcohol use disorder, 270–273
 - and binge eating disorder, 318
 - and bulimia nervosa, 314
 - caffeine, 284
 - causes of, 288–296
 - clinical descriptions of, 270–288
 - co-diagnoses with, 65
 - in DSM-5, 59, 267–270
 - effects of, 270–280, 282–283, 286–288
 - genetic influences, 288–289
 - hallucinogens, ecstasy, and PCP, 286–288
 - international prevalence of, 62
 - living conditions for people with, 22
 - marijuana, 276–279
 - neurobiological influences, 289–292
 - nitrous oxide, 287
 - and obsessive-compulsive related disorders, 188
 - opioids, 280–283
 - prevalence of, 267–270, 273–274, 280–292, 283
 - prevention of, 305
 - psychological influences, 292–294
 - sociocultural influences, 294–295
 - stimulants, 283–286
 - on television shows, 22
 - tobacco use disorder, 273–276
 - treatment of, 296–306
 - SUDS (Subjective Units of Distress Scale), 95
 - Suicidal behavior
 - and antidepressants, 382–385
 - and borderline personality disorder, 444–445
 - and dialectical behavior therapy, 93
 - and schizophrenia, 238
 - Suicidal ideation, 142–143, 146
 - Suicidality, treatment for, 145–146
 - Suicide
 - and ADHD, 368
 - and anorexia nervosa, 312
 - and bipolar disorders, 121
 - and bulimia nervosa, 314
 - attempts, 142–144
 - epidemiology of, 143–144
 - and mood disorders, 142–149
 - and nonsuicidal self-injury, 143
 - preventing, 146–148
 - risk factors for, 144–146
 - Superego, 17
 - Supernatural, as cause of psychological disorders, 8–10
 - Support groups, 5
 - Surgeon General of the United States, 260, 273
 - Surveys, of sexual behavior, 341
 - Susto*, 160
 - Sybil* (Schreiber), 217
 - Sybil*, 219
 - Symbolic play (SP), 402
 - Sympathetic nervous system, 33
 - Symptoms, 59
 - Synapses, 33
 - Syndrome, 58
 - Synthesis, 454
 - Synthetic marijuana, 276
 - Systematic desensitization, 99
- T**
- Tadalafil (Cialis), 352
 - TADS (Treatment of Adolescents with Depression Study), 382–384
 - Taijin kyofusho*, 61, 160
 - Tarasoff, Tatiana (Tanya), 473–474
 - Tardive dyskinesia, 258
 - Tarloff, David, 459
 - TAT (Thematic Apperception Test), 73
 - Tchaikovsky, Piotr Ilych, 122
 - tDCS (transcranial direct current stimulation), 79
 - Teacher training approaches (conduct disorder), 378
 - Teenagers. *See* Adolescents
 - Television shows, people with psychological disorders on, 22
 - Temporal cortex, 252
 - Temporal lobes, 397
 - Tension, effects of alcohol and nicotine on, 292
 - Test anxiety, 152
 - Testosterone, 346
 - Test-retest reliability, 54. *See also* Reliability
 - Texas, 462, 466, 469
 - Thailand, 301, 366
 - THC (delta-9-tetrahydrocannabinol), 278
 - Thematic Apperception Test (TAT), 73
 - Theory, 84–85
 - Theory of mind, 397
 - Therapeutic effect, of marijuana, 279
 - Therapists
 - recovered memories, 216
 - reinforcement of DID symptoms by, 220
 - Thesis, 454
 - Thimerosal, 384
 - Thinking in Pictures* (film), 399
 - Thinness, 311, 323–327
 - Thiothixene (Navane), 259
 - Third-variable problem, 86, 90
 - Thorazine, 258, 259
 - Thorndike, Edward, 20
 - Thought-action fusion, 191
 - Thought broadcasting, 239
 - Thought disorders, 435
 - Thought insertion, 239
 - Thought suppression, 191
 - Threat(s)
 - anxiety disorders and attention to, 163, 166–167
 - psychopathy and response to, 443–444

- Three Faces of Eve, The* (Thigpen & Cleckley), 217
- Timeline Follow Back (TLFB) interview, 299
- Time-of-measurement effects, 408
- Time-out, 40
- TLFB (Timeline Follow Back) interview, 299
- TMS (transcranial magnetic stimulation), 79
- Tobacco Education Media Campaign, 274
- Tobacco use disorder, 273–276
and e-cigarettes, 275–276
genetic influences, 288–289
health consequences of
secondhand smoke, 275
prevalence and health
consequences of smoking,
273–274
treatments for, 301
- Tolerance, 268–269, 279
- Torture, 480
- Touched with Fire* (Jamison), 122
- Tourette's disorder, 390
- Toxic effect model (substance dependence), 290
- Toxoplasma gondii*, 253
- Trail Making Test, 75
- Training, 4, 81–82
- Tramadol, 282
- Transcranial direct current stimulation (tDCS), 79
- Transcranial magnetic stimulation (rTMS), 79, 140
- Transcription, 29
- Transference, 17
- Transference-focused therapy, 454
- Transinstitutionalization, 477
- Transvestic disorder, 353
- Trauma, 168, 198, 199, 202–203, 254–255
- Trauma-related disorders, 198–207
anxiety disorders and, 153
clinical descriptions of, 198–201
epidemiology of, 198–201
ethnicity and prevalence of, 46
etiology of, 201–204
gender differences in, 46
treatment of, 205–207
- Treatment(s). *See also*
Psychotherapy; under
specific headings, e.g.-
Eating
disorders empirically
supported, 99
neuroscience approaches to, 38
right to, 475–476
right to refuse, 478
- Treatment Advocacy Center, 12, 478
- Treatment-as-usual control group, 101
- Treatment manuals, 100
- Treatment of Adolescents with Depression Study (TADS), 382–384
- Treatment outcome research, 98–105
assessment in, 104
- control groups in, 101
defined, 98
dissemination of findings from, 104
effect sizes in, 110
samples in, 101–102
treatment condition in, 100
- Tremors, 231
- Trial, competency to stand, 464–468
- Tricyclic antidepressants, 138
- Trifluoperazine (Stelazine), 259
- Trisomy 21, 392
- Tunnel vision, 225
- Turkish earthquake of 2023, 202
- 12 steps of Alcoholics Anonymous, 298
- Twin method, 93
- Twin studies
of ADHD, 370
of anxiety disorders, 164, 172
of autism spectrum disorder, 400
of conduct disorder, 375–376
of depression, 128
of eating disorders, 319
of pedophilic disorder, 347
of schizophrenia, 246–248
of substance use disorders, 289
of suicide risk, 145
- Two-factor model of conditioning, 162, 169
- Tylox, 281
- U**
- UCR (unconditioned response), 19. *See also* Classical conditioning
- UCS (unconditioned stimulus), 19. *See also* Classical conditioning
- Ukraine, 102
- Uncertainty, intolerance for, 166
- Unconditioned response (UCR), 19. *See also* Classical conditioning
- Unconditioned stimulus (UCS), 19. *See also* Classical conditioning
- Unconscious, 16, 18, 41–42, 231
- Unemotional traits, 374, 376
- Unexplained blindness, 231
- Unique environment, 27
- United Kingdom, 58, 262, 273, 331, 383–384. *See also* England
- United States
alcohol consumption, 91, 102
antidepressants in, 134, 382–384
anxiety disorders, 153
autism spectrum disorders, 383–384
binge eating disorder in, 314
civil liberties of sex offenders, 362–363
community-based care, 265
drug use, 268
eating disorders in, 325
expectations about sex drive, 343
ideal affect, 45
- internalizing and externalizing behavior problems, 367
- lifetime prevalence rates of diagnoses in, 91
- methamphetamine use, 268
- moral treatment in, 11–12
- obesity in, 315–316
- older adult population of, 406–407
- opioid addiction, 282
- panic attacks, 157
- people seeking treatment, 102
- preoccupation with food in, 308
- prevalence of PTSD in, 201
- rape in, 359
- rates of psychological disorders, 59–62
- sexual norms, 338
- smoking cessation programs in, 291
- substance use disorders, 271
- suicide and suicide attempt rates, 144
- tobacco use in, 274
- Universal prevention programs for depression, 385
- University of California, 473–474
- Unresolved grief, 48
- “Unspecified” category, DSM, 62
- Unstructured clinical interviews, 432
- Upp, Hannah, 214
- Urbanicity, 254–255
- U.S. Department of Agriculture, 316
- U.S. Department of Health and Human Services, 481
- U.S. Department of Health, Education, and Welfare, 481
- U.S. Supreme Court, 14, 362, 461, 463, 465, 468, 469–470, 473–476
- Utah, 275, 463
- V**
- Vaccines, 384
- Vaginal plethysmograph, 338
- Vaginismus, 344
- Validity, 55–56
construct, 55
content, 55
criterion, 55
in diagnosis and assessment, 55–56
of DSM diagnostic categories, 66–67
external, 94
internal, 94
- Validity scales, 73
- VAMC (Veterans Affairs Medical Center), 206
- Vaping, 275–276
- Vardenafil (Levitra), 352
- Varenicline (Chantix), 301
- Variables
correlation of, 87
dependent, 86, 93
independent, 86, 93
third-variable problem, 86, 90
- Vascular dementia, 416, 420–421
- Ventral striatum, 320
- Ventricles, 34, 251
- Veterans Administration, 7, 12, 132
- Veterans Affairs Medical Center (VAMC), 206
- Viagra (sildenafil), 330
- Vicodin, 281
- Vietnam War, 199
- Violence, 359, 442, 471–472
- Virginia, 470
- Virtual reality (VR) technology, 176, 206
- Voucher treatments, 302
- Voyeuristic disorder, 353, 355, 358
- VR (Virtual reality) technology, 176, 206
- Vulnerability model of substance dependence, 290
- W**
- WAIS-IV (Wechsler Adult Intelligence Scale, 4th edition), 74
- Wales, 294
- Wanting, neurobiology of, 290–291, 320
- Washington, D.C., 460–461
- Watson, John B., 19
- Wechsler Adult Intelligence Scale, 4th edition (WAIS-IV), 74
- Wechsler Intelligence Scale for Children, 5th edition (WISC-V), 74
- Wechsler Preschool and Primary Scale of Intelligence, 4th edition (WPPSI-IV), 74
- Weight, stigma about, 308–309
- Weight gain, as side effect, 260
- Wellbutrin (bupropion), 301
- Were* (Yoruba concept), 45
- Wernicke, Carl, 14
- Wernicke's area, 240
- Western cultures
body dysmorphic disorder in, 186
ideal affect in, 45
self-reports of sexual dysfunction symptoms in, 354
sexual norms in, 336
thinness and eating disorders in, 325
- Whippets, 287
- White matter, 34
- Whites, 46, 102, 271, 274, 260, 282, 287, 299, 327. *See also*; European Americans
- WHO (World Health Organization), 58, 316
- Williams, Ricky, 179
- Williams, Robin, 145
- Wind attacks, 61
- Wine, 271
- WISC-V (Wechsler Intelligence Scale for Children, 5th edition), 74
- Withdrawal, 268
alcohol, 270, 297
avoiding symptoms of, 290
caffeine, 284
and drug use disorders, 301
marijuana, 279
opioid, 282–283

Wolf of Wall Street, The (film), 442
 Women. *See* Gender
 Woolf, Virginia, 146
 World Health Organization (WHO), 58, 316
 World Mental Health Survey, 91, 102, 121, 201
 World War II, 202, 481
 Worry(-ies), 158, 178, 383

WPPSI-IV (Wechsler Preschool and Primary Scale of Intelligence, 4th edition), 74
 Wright, Frank Lloyd, 447
 Writings, recovered memories from, 216
Wyatt v. Stickney, 475

X
 Xanax (alprazolam), 38

Y
 Yates, Andrea, 465
 Yoruba, 45
 Young adults
 advertising and substance use by, 299
 drug use trends for, 277
 smoking cessation programs for, 301

Young children, PTSD symptoms of, 386
 Youth Emotion Project, 381

Z
 Zimbabwe, 294, 325
 Ziprasidone (Geodon), 259
 Zolofit (sertraline), 138, 388
 Zydene, 281
 Zyprexa (Olanzapine), 259, 260

